[["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0018874",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","4ae73ff84315f4739f4877764dea1b6c2088dc0399290df9bd91d14d32c298a3"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 10, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.90622773115795, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7015993\", \"PMC:8469858\", \"PMC:9135597\", \"PMC:6851194\", \"PMC:6679203\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:4c45dc40c60aeb1585eda88b6d2cfab64a18e46a1e0001359b044590698456c4\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/4c45dc40c60aeb1585eda88b6d2cfab64a18e46a1e0001359b044590698456c4\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"With its prominent oncogenic roles, AXL has been proposed as a therapeutic target for TNBC and also for other cancers, and one of its selective inhibitors R428 (BGB324; Bemcentinib) is under clinical trials for acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) (NCT02488408/NCT02424617) as well as for advanced TNBC and adenocarcinoma of the lung in combination with pembrolizumab.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7015993\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7015993/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9063047255986045, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"169|180\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"211|233\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:42f1d20c7c36abe667d1db9a5f0bacdd528f91600d60cef5bdefef4a2d02e6d0\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/42f1d20c7c36abe667d1db9a5f0bacdd528f91600d60cef5bdefef4a2d02e6d0\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib entered clinical trials as the first Axl-specific inhibitor and is undergoing Phase I/II clinical trials for melanoma, non-small-cell lung cancer (NSCLC), mesothelioma, acute myeloid leukemia, glioblastoma, and pancreatic adenocarcinoma (Clinical Trial Identification Numbers: NCT02872259; NCT02922777; NCT03184571; NCT03654833; NCT03824080; NCT03965494; NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8469858\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8469858/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9062389842613362, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"181|203\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:59fb840641c7986a62b4b778962bb0170dfe0beff1e3d06e71d29548166c2d40\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/59fb840641c7986a62b4b778962bb0170dfe0beff1e3d06e71d29548166c2d40\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Given this, AXL is a promising therapeutic target, and R428 (bemcentinib), a first-in-class AXL kinase inhibitor, is currently being evaluated in phase 2 clinical trials for metastatic lung and triple-negative breast cancer, glioblastoma, and acute myeloid leukemia.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9135597\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9135597/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9062386215505098, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"61|72\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"243|265\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:b26f7cc0b04f3c3193265be036f7f2541c98eb857a45ad213f054f5d025084ae\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/b26f7cc0b04f3c3193265be036f7f2541c98eb857a45ad213f054f5d025084ae\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"R428 (bemcentinib, BGB324), a selective small-molecule inhibitor of AXL, is currently being evaluated in phase II trials for the treatment of non-small-cell lung cancer (NSCLC) and acute myelocytic leukemia (AML).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6851194\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6851194/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9061794543469682, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"6|17\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"181|206\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:f0acbf57ddaf9dcb2638b7b8accb31284e49e1eccacde6761ea241cfd44334dc\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/f0acbf57ddaf9dcb2638b7b8accb31284e49e1eccacde6761ea241cfd44334dc\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6679203\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6679203/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"reference\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9061768700323307, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"33|44\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"138|160\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0018874"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7015993|PMC:8469858|PMC:9135597|PMC:6851194|PMC:6679203"],["score","0.90622773115795"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:4c45dc40c60aeb1585eda88b6d2cfab64a18e46a1e0001359b044590698456c4|tmkp:42f1d20c7c36abe667d1db9a5f0bacdd528f91600d60cef5bdefef4a2d02e6d0|tmkp:59fb840641c7986a62b4b778962bb0170dfe0beff1e3d06e71d29548166c2d40|tmkp:b26f7cc0b04f3c3193265be036f7f2541c98eb857a45ad213f054f5d025084ae|tmkp:f0acbf57ddaf9dcb2638b7b8accb31284e49e1eccacde6761ea241cfd44334dc"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0008383",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","3aa87eaa8c25e75ebf409cb39dabb7ef48306c7cf09634397027e768b5f9ab96"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8712096028436658, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7516369\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:fb6bcc7ea3fd18e244500a84bf42bea982c7d027d184847fe8193033f21712ec\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/fb6bcc7ea3fd18e244500a84bf42bea982c7d027d184847fe8193033f21712ec\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Baricitinib [a Janus kinase (JAK) inhibitor marketed under the brand name Olumiant for the treatment of rheumatoid arthritis] and Bemcentinib (an AXL receptor tyrosine kinase inhibitor earlier found effective against Ebola and Zika viruses in preclinical studies) are currently under phase 3 and phase 2 clinical investigations.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7516369\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7516369/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8712096028436658, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"130|141\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"104|124\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0008383"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7516369"],["score","0.8712096028436658"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:fb6bcc7ea3fd18e244500a84bf42bea982c7d027d184847fe8193033f21712ec"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0018177",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","36f05685133f74f9019db7d9375f883fb6e16d58ab28f4b737b113e9484861fb"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 7, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9470858882888452, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9354051\", \"PMC:7912673\", \"PMC:9135597\", \"PMC:8469858\", \"PMC:8616823\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:03eadfea1c94e252bd895cba71f34ec36680a16d37307b310d7fc196e0cbe5bb\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/03eadfea1c94e252bd895cba71f34ec36680a16d37307b310d7fc196e0cbe5bb\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"However, a prior study revealed that cell treatment with bemcentinib suppressed autophagy in an AXL-independent mechanism in glioblastoma cells.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9354051\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9354051/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9471306146887415, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"57|68\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"125|137\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:edeb65b4fd434585e1690a4208fb0f0b4764390724677b76323979d5104f0d23\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/edeb65b4fd434585e1690a4208fb0f0b4764390724677b76323979d5104f0d23\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"There are five active clinical trials testing the Axl inhibitor BGB324 (bemcentinib), including a phase 1 trial in GBM (NCT03965494).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7912673\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7912673/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9471086959288448, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"72|83\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"115|118\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:39f4eec9ffd69aeedcb8230c065853aa74e1f3d74241945c9ae66f095f5a623a\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/39f4eec9ffd69aeedcb8230c065853aa74e1f3d74241945c9ae66f095f5a623a\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Given this, AXL is a promising therapeutic target, and R428 (bemcentinib), a first-in-class AXL kinase inhibitor, is currently being evaluated in phase 2 clinical trials for metastatic lung and triple-negative breast cancer, glioblastoma, and acute myeloid leukemia.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9135597\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9135597/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.947077679888576, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"61|72\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"225|237\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5e501f81250ba8ea47c4a9b70f28ab100a23f7596cec38bb52ed9a0d2aa5f3c8\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5e501f81250ba8ea47c4a9b70f28ab100a23f7596cec38bb52ed9a0d2aa5f3c8\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib entered clinical trials as the first Axl-specific inhibitor and is undergoing Phase I/II clinical trials for melanoma, non-small-cell lung cancer (NSCLC), mesothelioma, acute myeloid leukemia, glioblastoma, and pancreatic adenocarcinoma (Clinical Trial Identification Numbers: NCT02872259; NCT02922777; NCT03184571; NCT03654833; NCT03824080; NCT03965494; NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8469858\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8469858/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9470662798591096, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"205|217\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:b20d138b7cfa21ae2e3540ec1bdfb174506b947e5f489824d5616f81632e3a42\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/b20d138b7cfa21ae2e3540ec1bdfb174506b947e5f489824d5616f81632e3a42\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The AXL inhibitor bemcentinib (also known as BGB324) is now being tested in a phase I trial for recurrent GBM as a monotherapy (TABLE 2), but dual inhibition of PD1 and AXL has been shown to extend survival in preclinical models of melanoma BrMs and GBM.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8616823\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8616823/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9470461710789538, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"18|29\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"106|109\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0018177"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9354051|PMC:7912673|PMC:9135597|PMC:8469858|PMC:8616823"],["score","0.9470858882888452"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:03eadfea1c94e252bd895cba71f34ec36680a16d37307b310d7fc196e0cbe5bb|tmkp:edeb65b4fd434585e1690a4208fb0f0b4764390724677b76323979d5104f0d23|tmkp:39f4eec9ffd69aeedcb8230c065853aa74e1f3d74241945c9ae66f095f5a623a|tmkp:5e501f81250ba8ea47c4a9b70f28ab100a23f7596cec38bb52ed9a0d2aa5f3c8|tmkp:b20d138b7cfa21ae2e3540ec1bdfb174506b947e5f489824d5616f81632e3a42"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0003634",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","36c33ab78ec57368798ea1ae7952461284a371beb556487888d8b6afc88ef54e"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.982396119772393, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:6536582\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:0db9cb78fef4ccef5ccd91da6acef57a9e1ee311c05e429afba1dc4c261d6cdc\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/0db9cb78fef4ccef5ccd91da6acef57a9e1ee311c05e429afba1dc4c261d6cdc\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Therefore, further experiments should employ renal fibrosis models that enable functional read?outs to investigate whether inhibition of fibrosis progression by bemcentinib treatment leads to improved glomerular filtration rate and reduced proteinuria.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6536582\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6536582/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.982396119772393, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"161|172\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"240|251\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0003634"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:6536582"],["score","0.982396119772393"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:0db9cb78fef4ccef5ccd91da6acef57a9e1ee311c05e429afba1dc4c261d6cdc"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0012817",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","32a69038cb59daf111af2f96ee067bb5c760519cedbf20ec6d2d404e9f5fefaf"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0842430789284412, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7381324\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:81b61d9e2aebd222ca635b6669559a84a54b496afff55620cc29b80cfbaca917\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/81b61d9e2aebd222ca635b6669559a84a54b496afff55620cc29b80cfbaca917\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib (BGB324), an AXL inhibitor, in combination with vincristine (a mitotic inhibitor), showed a synergistic therapeutic effect, reducing cell viability and migration of high AXL- and Gas6-expressing ES cells (Table 3).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7381324\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7381324/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0842430789284412, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"207|209\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0012817"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7381324"],["score","1.0842430789284412"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:81b61d9e2aebd222ca635b6669559a84a54b496afff55620cc29b80cfbaca917"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","HP:0004808",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","29140d7b12b3e47764db7f0e929b7b882e9160ebf1fa3ac3114bbcaa015c0d71"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 3, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9994142166666666, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:6679203\", \"PMC:9157040\", \"PMC:9157040\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:48e9df02f339c0451a43ff8bfcab9c79caf56ab8d0566dd6a4e08a7d4c9140df\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/48e9df02f339c0451a43ff8bfcab9c79caf56ab8d0566dd6a4e08a7d4c9140df\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"However, only bemcentinib (R428, BGB324) is currently being tested in AML.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6679203\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6679203/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9995103, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"14|25\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"70|73\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:db91c7929558c85ea403ab83757a0d09edea539205103cc2ed60fe3dbe5b3eb0\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/db91c7929558c85ea403ab83757a0d09edea539205103cc2ed60fe3dbe5b3eb0\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib is currently in phase II clinical trials (NCT03824080) for acute myeloid leukaemia (AML) and low/high-risk myelodysplastic syndrome (Table?1).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9157040\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9157040/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.99940765, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"96|99\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:4ba24eabcba35ab874e9c73b042f955abab472a61944295db62c4590720ae779\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/4ba24eabcba35ab874e9c73b042f955abab472a61944295db62c4590720ae779\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib is currently in phase II clinical trials (NCT03824080) for acute myeloid leukaemia (AML) and low/high-risk myelodysplastic syndrome (Table?1).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9157040\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9157040/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9993247, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"71|94\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","3"],["object","HP:0004808"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:6679203|PMC:9157040|PMC:9157040"],["score","0.9994142166666666"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:48e9df02f339c0451a43ff8bfcab9c79caf56ab8d0566dd6a4e08a7d4c9140df|tmkp:db91c7929558c85ea403ab83757a0d09edea539205103cc2ed60fe3dbe5b3eb0|tmkp:4ba24eabcba35ab874e9c73b042f955abab472a61944295db62c4590720ae779"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0006292",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","25e7ca1a18924972332735fa27f0b82180adc8b50fb78ed94795e10529d8c9fb"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.083990688634705, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8357258\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:c579adda43eb0e090dba75cfb7a2e05b8350f1ca5be821c00f3052c9adabcdf7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/c579adda43eb0e090dba75cfb7a2e05b8350f1ca5be821c00f3052c9adabcdf7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Currently, bemcentinib is studied in combination with chemotherapy, immunotherapy, or targeted therapies in non-small cell lung cancer (NCT03184571, NCT02922777, NCT02424617), triple negative breast cancer (NCT03184558), pancreatic cancer (NCT03649321), glioblastoma (NCT03965494), malignant mesothelioma (NCT03654833), and melanoma (NCT02872259).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.083990688634705, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"11|22\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"282|304\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0006292"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8357258"],["score","1.083990688634705"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:c579adda43eb0e090dba75cfb7a2e05b8350f1ca5be821c00f3052c9adabcdf7"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0019457",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","23b933ac04771341fd187fbe8ee85ead33f780e7c4b5cd9d1340de953fe3e904"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 6, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.2532858082096963, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7413899\", \"PMC:7413899\", \"PMC:7413899\", \"PMC:7413899\", \"PMC:7413899\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:39a93cd947c8f1eee522bc4805904d585963fe57e45d0349227b09303514ab7b\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/39a93cd947c8f1eee522bc4805904d585963fe57e45d0349227b09303514ab7b\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib (BGB324) is an inhibitor of the AXL receptor whose therapeutic effect on sAML is currently under investigation in clinical phase II trials.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7413899\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7413899/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.2533634215432987, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"85|89\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:8e01cd4c51356e22b8a4de1b8258a3f5b352b8403cadc0c1c9dd2e1c0d9062a6\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/8e01cd4c51356e22b8a4de1b8258a3f5b352b8403cadc0c1c9dd2e1c0d9062a6\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"An 81-year-old male patient with a diagnosis of secondary acute myeloblastic leukemia (sAML) treated with the AXL inhibitor Bemcentinib for 2 months as part of a phase II trail was referred to the outpatient clinic of the Department of Conservative Dentistry and Periodontology, University Hospital Munich due to exposed alveolar bone of the upper anterior jaw persisting for approximately 4?5 weeks in June 2019.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7413899\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7413899/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"CASE\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.253326053182208, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"124|135\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"48|85\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:1a59139049815a62a8c5d3a46677547c7951467d8f9cee099cb71f24cf1798be\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/1a59139049815a62a8c5d3a46677547c7951467d8f9cee099cb71f24cf1798be\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Herein, we report a case of medication-related osteonecrosis of the upper jaw after Bemcentinib regimen for the treatment of secondary acute myeloblastic leukemia.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7413899\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7413899/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.253298465801537, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"84|95\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"125|162\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:d02b6644cd1bed9b628cd5768972b8aa92a04995f453c2c676dec70297eef899\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/d02b6644cd1bed9b628cd5768972b8aa92a04995f453c2c676dec70297eef899\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"We present a male 81-year-old patient with a manifestation of alveolar bone necrosis at the central upper incisors following a 2-month regimen with the AXL-inhibitor Bemcentinib, administered for the treatment of secondary acute myeloblastic leukemia (sAML).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7413899\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7413899/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.2532659001526265, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"166|177\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"213|250\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:2066df948f7a0515eaba4b5486946db883d3dc238f209f967de82ea449e096db\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/2066df948f7a0515eaba4b5486946db883d3dc238f209f967de82ea449e096db\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"An 81-year-old male patient with a diagnosis of secondary acute myeloblastic leukemia (sAML) treated with the AXL inhibitor Bemcentinib for 2 months as part of a phase II trail was referred to the outpatient clinic of the Department of Conservative Dentistry and Periodontology, University Hospital Munich due to exposed alveolar bone of the upper anterior jaw persisting for approximately 4?5 weeks in June 2019.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7413899\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7413899/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"CASE\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.2531752003688112, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"124|135\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"87|91\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","6"],["object","MONDO:0019457"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7413899|PMC:7413899|PMC:7413899|PMC:7413899|PMC:7413899"],["score","1.2532858082096963"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:39a93cd947c8f1eee522bc4805904d585963fe57e45d0349227b09303514ab7b|tmkp:8e01cd4c51356e22b8a4de1b8258a3f5b352b8403cadc0c1c9dd2e1c0d9062a6|tmkp:1a59139049815a62a8c5d3a46677547c7951467d8f9cee099cb71f24cf1798be|tmkp:d02b6644cd1bed9b628cd5768972b8aa92a04995f453c2c676dec70297eef899|tmkp:2066df948f7a0515eaba4b5486946db883d3dc238f209f967de82ea449e096db"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0002691",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","face58b8555af241fecac19f68ef8709e711fa10d13f27d847bea4ca339c0404"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8465945799383676, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7013198\", \"PMC:7013198\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:18f2f058fc4384de75ecc4dee61ad78e31bd675e02f97251577214697c012cfb\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/18f2f058fc4384de75ecc4dee61ad78e31bd675e02f97251577214697c012cfb\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Therefore, an antitumoral action of bemcentinib could be an additional benefit for NASH individuals, predisposed to develop liver cancer due to their protumorigenic liver microenvironment.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7013198\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7013198/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8466128391236097, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"36|47\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"124|136\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:ae9d0a003343624a8cccd4ef6cba1b14fabbafcbb9339abe937e6035dbbbf7d9\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/ae9d0a003343624a8cccd4ef6cba1b14fabbafcbb9339abe937e6035dbbbf7d9\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Interestingly, AXL inhibition by bemcentinib potentiates antitumor immune response, especially in combination with checkpoint inhibitors such as the anti-PD-1 agent nivolumab, recently Food and Drug Administration?approved for advanced liver cancer.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7013198\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7013198/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8465763207531255, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"33|44\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"236|248\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0002691"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7013198|PMC:7013198"],["score","0.8465945799383676"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:18f2f058fc4384de75ecc4dee61ad78e31bd675e02f97251577214697c012cfb|tmkp:ae9d0a003343624a8cccd4ef6cba1b14fabbafcbb9339abe937e6035dbbbf7d9"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005061",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","f91fba0257e67122b4cbfa2440fb56ad97355052ff139873fa74692986124f71"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 8, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0453851629831585, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7408754\", \"PMC:7015993\", \"PMC:8581356\", \"PMC:8179919\", \"PMC:8833442\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:9384eca481904a998f039ba1a1aab81a0b49896a8b9f961a99823def9cf00254\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/9384eca481904a998f039ba1a1aab81a0b49896a8b9f961a99823def9cf00254\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Indeed, pharmacologic Axl inhibition using a selective Axl inhibitor, bemcentinib or BGB324, in lung adenocarcinoma cell lines (PC9 and H1975) significantly decreased PD-L1 and PD-L2, another ligand that binds to PD-1.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7408754\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7408754/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0454527823340898, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"69|80\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"95|114\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:7503da4c0ede97ac11379ca64cae21208e84639d79ed1e361b0cde579f7175e8\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/7503da4c0ede97ac11379ca64cae21208e84639d79ed1e361b0cde579f7175e8\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"With its prominent oncogenic roles, AXL has been proposed as a therapeutic target for TNBC and also for other cancers, and one of its selective inhibitors R428 (BGB324; Bemcentinib) is under clinical trials for acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) (NCT02488408/NCT02424617) as well as for advanced TNBC and adenocarcinoma of the lung in combination with pembrolizumab.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7015993\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7015993/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0454290890959692, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"169|180\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"335|361\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:3dac46b3342b73885610c505fe36bae28509736ef933afd410d9746eba453a92\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/3dac46b3342b73885610c505fe36bae28509736ef933afd410d9746eba453a92\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Lung adenocarcinoma cell lines (PC9 and H1975) subjected to AXL inhibition by either bemcentinib or BGB324 significantly decreased PD-L1.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8581356\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8581356/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0453906464248464, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"85|96\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"0|19\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:db211f3bbcb7dd54f94349b843d62c733c98a6fb4d9fd1904c07b7eca60f4270\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/db211f3bbcb7dd54f94349b843d62c733c98a6fb4d9fd1904c07b7eca60f4270\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib (BGB324), a specific type I kinase inhibitor of Axl with promising preclinical results has entered clinical trials for cancers including non-small cell lung carcinoma, adenocarcinoma of the lung, acute myeloid leukemia, melanoma and pancreatic cancer (obtained from ClinicalTrials.gov).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8179919\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8179919/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0453674239133106, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"180|206\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5fc444edee28adc5f4746b724c00116013520ef7a93b28d7fa6d65f6c81f440c\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5fc444edee28adc5f4746b724c00116013520ef7a93b28d7fa6d65f6c81f440c\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"A phase II trial of bemcentinib, an oral AXL inhibitor, in combination with pembrolizumab in patients with TNBC and adenocarcinoma of the lung, has completed data collection and results are pending.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8833442\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8833442/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0452858731475763, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"20|31\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"116|142\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0005061"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7408754|PMC:7015993|PMC:8581356|PMC:8179919|PMC:8833442"],["score","1.0453851629831585"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:9384eca481904a998f039ba1a1aab81a0b49896a8b9f961a99823def9cf00254|tmkp:7503da4c0ede97ac11379ca64cae21208e84639d79ed1e361b0cde579f7175e8|tmkp:3dac46b3342b73885610c505fe36bae28509736ef933afd410d9746eba453a92|tmkp:db211f3bbcb7dd54f94349b843d62c733c98a6fb4d9fd1904c07b7eca60f4270|tmkp:5fc444edee28adc5f4746b724c00116013520ef7a93b28d7fa6d65f6c81f440c"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0009831",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","f5b8e0209d6f717d861be41111d32a70e5da6f8cc817f7f8f17703afbb25a143"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 13, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8996845520783827, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7913382\", \"PMC:7408754\", \"PMC:8349827\", \"PMC:8179919\", \"PMC:8357258\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:38373a45c52a3bedc0293b66fe161cb2f9c649ff2423caee4f148968777f843d\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/38373a45c52a3bedc0293b66fe161cb2f9c649ff2423caee4f148968777f843d\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In this context, bemcentinib, also known as BGB324 or R428, has been investigated in clinical trials for the treatment of pancreatic cancer.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7913382\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7913382/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8997629370103242, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"17|28\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"122|139\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:363122a4974fd62ddfc5d312374078e071337818e29a9c69315a3348f6569c22\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/363122a4974fd62ddfc5d312374078e071337818e29a9c69315a3348f6569c22\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Similarly, in murine pancreatic cancer models, bemcentinib decreased tumor infiltrating macrophages.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7408754\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7408754/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8997194738474918, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"46|57\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"20|37\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:77235f95b8a29358064e248bab06fddf02d066c8b938cad173233099eb9070bb\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/77235f95b8a29358064e248bab06fddf02d066c8b938cad173233099eb9070bb\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The efficacy of bemcentinib in combination with chemotherapy is being tested currently in pancreatic cancer patients (NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8349827\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8349827/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8997178624336255, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"16|27\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"90|107\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:d344c0103dc12a5f87902f2f81c56f4ac28f00836581e1c1437f63192843be3f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/d344c0103dc12a5f87902f2f81c56f4ac28f00836581e1c1437f63192843be3f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib (BGB324), a specific type I kinase inhibitor of Axl with promising preclinical results has entered clinical trials for cancers including non-small cell lung carcinoma, adenocarcinoma of the lung, acute myeloid leukemia, melanoma and pancreatic cancer (obtained from ClinicalTrials.gov).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8179919\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8179919/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.899611671160061, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"245|262\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:960952ca339cf904a8423573b6d1fb8dec8425f9dd76c00c5415204543f0d86b\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/960952ca339cf904a8423573b6d1fb8dec8425f9dd76c00c5415204543f0d86b\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Currently, bemcentinib is studied in combination with chemotherapy, immunotherapy, or targeted therapies in non-small cell lung cancer (NCT03184571, NCT02922777, NCT02424617), triple negative breast cancer (NCT03184558), pancreatic cancer (NCT03649321), glioblastoma (NCT03965494), malignant mesothelioma (NCT03654833), and melanoma (NCT02872259).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8996108159404113, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"11|22\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"221|238\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","4"],["object","MONDO:0009831"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7913382|PMC:7408754|PMC:8349827|PMC:8179919|PMC:8357258"],["score","0.8996845520783827"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:38373a45c52a3bedc0293b66fe161cb2f9c649ff2423caee4f148968777f843d|tmkp:363122a4974fd62ddfc5d312374078e071337818e29a9c69315a3348f6569c22|tmkp:77235f95b8a29358064e248bab06fddf02d066c8b938cad173233099eb9070bb|tmkp:d344c0103dc12a5f87902f2f81c56f4ac28f00836581e1c1437f63192843be3f|tmkp:960952ca339cf904a8423573b6d1fb8dec8425f9dd76c00c5415204543f0d86b"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0008903",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","19acd4fb63b110f8c4d5454c6d74359555eed1bff92f6edc96e27e04ee340559"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8195683056839554, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9305809\", \"PMC:9092944\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:4b527ec84842bef7cd4ba8bf290e2da967cf801fef0f367fe9f845d2d0acaea0\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/4b527ec84842bef7cd4ba8bf290e2da967cf801fef0f367fe9f845d2d0acaea0\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In a preclinical lung cancer model, the combination of bemcentinib and anti-PD-L1 therapy significantly reduced tumor growth versus anti-PD-L1 therapy alone; tumors treated with the combination showed altered cytokine signaling, enhanced infiltration by effector cells, and a reduction in MDSCs.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9305809\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9305809/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8195812579064868, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"55|66\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"17|28\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:289f13dae315e200506cc355e1bdec7d6280f57f027e0bdfecc392f35122c78b\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/289f13dae315e200506cc355e1bdec7d6280f57f027e0bdfecc392f35122c78b\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In another cancer model, we have shown that bemcentinib abrogates autophagic flux in erlotinib-resistant lung cancer HCC827 cells, in association with increased cell surface expression of MHC I molecules, and markers of immunogenic cell death (ICD) revealed by the release of ATP, in addition to two other damage-associated molecular patterns (DAMPs); release of High Mobility Group Box 1 (HMGB1) and cell surface-exposed calreticulin (Figure?4).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9092944\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9092944/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.819555353461424, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"44|55\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"105|116\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0008903"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9305809|PMC:9092944"],["score","0.8195683056839554"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:4b527ec84842bef7cd4ba8bf290e2da967cf801fef0f367fe9f845d2d0acaea0|tmkp:289f13dae315e200506cc355e1bdec7d6280f57f027e0bdfecc392f35122c78b"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0000494",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","186c874f120a82111094d6f10a89a5c34e67a911b80eda28c51c6429d62ded9d"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 3, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.1367421923557026, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8335678\", \"PMC:8335678\", \"PMC:8335678\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:41012a18f1ef17d7f75fe6564fc9f323c084d01d16c2c5e023bb8784c5ec3549\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/41012a18f1ef17d7f75fe6564fc9f323c084d01d16c2c5e023bb8784c5ec3549\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In a previous study from our group, we found that tyrosine kinase receptor AXL is involved in the progression of renal fibrosis in a UUO murine model and that AXL inhibitor bemcentinib attenuates disease development.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8335678\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8335678/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.1422013127395771, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"173|184\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"113|127\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:2d33b8dd39c44cb25038e941bdd1015b36d59aa0ae107d4981c09a04922df5d6\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/2d33b8dd39c44cb25038e941bdd1015b36d59aa0ae107d4981c09a04922df5d6\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In this study, we investigated the effects of Axl?inhibitor bemcentinib on mitochondrial dysfunction associated with renal fibrosis.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8335678\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8335678/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.1420614833897935, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"60|71\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"117|131\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:f7e909e9508d0695eabc71efbeca2d4806112b5ec4a5dfb8023835e1afb96248\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/f7e909e9508d0695eabc71efbeca2d4806112b5ec4a5dfb8023835e1afb96248\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"However, this pattern was at least partially reverted in bemcentinib?, compared to vehicle?treated animals, thus indicating that bemcentinib has a potential beneficial effect on mitochondrial dysfunction occurring during renal fibrosis.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8335678\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8335678/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.1259637809377367, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"129|140\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"221|235\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","3"],["object","MONDO:0000494"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8335678|PMC:8335678|PMC:8335678"],["score","1.1367421923557026"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:41012a18f1ef17d7f75fe6564fc9f323c084d01d16c2c5e023bb8784c5ec3549|tmkp:2d33b8dd39c44cb25038e941bdd1015b36d59aa0ae107d4981c09a04922df5d6|tmkp:f7e909e9508d0695eabc71efbeca2d4806112b5ec4a5dfb8023835e1afb96248"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005184",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","f2075552a40d31848aa8b696499c7c35b5e6ec681f095efd11a43a4dadef0c5d"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 8, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0969247958708868, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7583676\", \"PMC:8349827\", \"PMC:8349827\", \"PMC:8508406\", \"PMC:7583676\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:4b4c94f3a42d9894fa19f6abe198497781f830f95615edf02771bae240d350b7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/4b4c94f3a42d9894fa19f6abe198497781f830f95615edf02771bae240d350b7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In PDAC models, bemcentinib induced epithelial differentiation, returned the tumor microenvironment to an immunostimulatory phenotype, and sensitized PDAC to chemotherapy.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7583676\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7583676/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0970212145228633, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"16|27\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"150|154\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:b317e41b7b00862350ebd22e7248271e2a5441bdfc845d7137dfcf5878cf049e\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/b317e41b7b00862350ebd22e7248271e2a5441bdfc845d7137dfcf5878cf049e\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"We recently demonstrated the efficacy of a selective small molecular inhibitor of AXL, bemcentinib (BGB324) in combination with gemcitabine in multiple mouse models of PDA.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8349827\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8349827/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0969512934375845, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"87|98\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"168|171\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:bb9c1cbd5557194d03566392a1790f8fb0dbbe4ce6b64a1c62c213f889d3a55c\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/bb9c1cbd5557194d03566392a1790f8fb0dbbe4ce6b64a1c62c213f889d3a55c\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"For example, bemcentinib (BGB324), a selective AXL inhibitor, sensitizes PDA mouse models to gemcitabine treatment and promotes an immune stimulatory landscape.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8349827\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8349827/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0969377921919183, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"13|24\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"73|76\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5eb89c5b6f794537f17e17b078a4dd1c4ed025289a8e79495a9a72a33f0df548\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5eb89c5b6f794537f17e17b078a4dd1c4ed025289a8e79495a9a72a33f0df548\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"An ongoing clinical trial is testing the addition of bemcentinib (BGB324), a first class selective oral inhibitor of AXL to nab-paclitaxel/gemcitabine/cisplatin in the treatment of PDAC, and another trial is using another Axl inhibitor (TP-0903).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8508406\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8508406/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0969082650774127, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"53|64\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"181|185\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5fd2cd81940791d1c91aca809a2846342e6d41f5edea1be504bbe2d96592888c\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5fd2cd81940791d1c91aca809a2846342e6d41f5edea1be504bbe2d96592888c\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Early phase clinical trials evaluating bemcentinib in combination with standard of care cytotoxic chemotherapy are ongoing across a variety of malignancies including PDAC.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7583676\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7583676/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0968054141246555, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"39|50\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"166|170\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0005184"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7583676|PMC:8349827|PMC:8349827|PMC:8508406|PMC:7583676"],["score","1.0969247958708868"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:4b4c94f3a42d9894fa19f6abe198497781f830f95615edf02771bae240d350b7|tmkp:b317e41b7b00862350ebd22e7248271e2a5441bdfc845d7137dfcf5878cf049e|tmkp:bb9c1cbd5557194d03566392a1790f8fb0dbbe4ce6b64a1c62c213f889d3a55c|tmkp:5eb89c5b6f794537f17e17b078a4dd1c4ed025289a8e79495a9a72a33f0df548|tmkp:5fd2cd81940791d1c91aca809a2846342e6d41f5edea1be504bbe2d96592888c"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005627",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","f0bf32ffe862a0d681bcdf26b03e3e7b0f7e4b6a78e5ee08425d998d1ca20676"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8644144470137494, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8652404\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5f65146c640030ba3a803b103653c60711212cdc15607f4f574bddb050c5431f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5f65146c640030ba3a803b103653c60711212cdc15607f4f574bddb050c5431f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Moreover, the addition of bemcentinib has been reported to overcome resistance to EGFR inhibitors in experimental head and neck cancer cell line (Giles et al.,).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8644144470137494, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"26|37\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"114|134\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0005627"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8652404"],["score","0.8644144470137494"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:5f65146c640030ba3a803b103653c60711212cdc15607f4f574bddb050c5431f"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0013209",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","e9f5a25656ddc386b962e87dce40eaa5aa95efffadd60cf8b21dc566d6a2df83"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0903552976151771, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8698495\", \"PMC:8698495\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:43aa306e37ee799a898936ebc0577034413323fe63982e09e325572a9a47c2fe\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/43aa306e37ee799a898936ebc0577034413323fe63982e09e325572a9a47c2fe\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In a recent study conducted by Tutusaus A. et al. (2020), AXL inhibition using Bemcentinib was found to reduce lipid accumulation and overall NAFLD score, in mice fed on high fat diet.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8698495\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8698495/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0904702577828709, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"79|90\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"142|147\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:9f038090f300388203292a62c0693ae2a842cd1e4800cb45031392f1a90a3e33\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/9f038090f300388203292a62c0693ae2a842cd1e4800cb45031392f1a90a3e33\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"However, a few experimental reports mentioned in Table 1 demonstrate the use of RTK inhibitors such as Gefitinib, Bemcentinib and Sunitinib targeting EGFR, AXL and VEGFR respectively in NAFLD management.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8698495\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8698495/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0902403374474836, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"114|125\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"186|191\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0013209"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8698495|PMC:8698495"],["score","1.0903552976151771"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:43aa306e37ee799a898936ebc0577034413323fe63982e09e325572a9a47c2fe|tmkp:9f038090f300388203292a62c0693ae2a842cd1e4800cb45031392f1a90a3e33"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005138",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","e67563af31ee93a09d4ae15f726d33b10e66b673ffc3af2b62b2da125736223a"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8880942269527965, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7397559\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:7830dbf2d0d5927ddf6c59f013aad5cf625bf6444cf256e60986952e202f3e17\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/7830dbf2d0d5927ddf6c59f013aad5cf625bf6444cf256e60986952e202f3e17\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Despite the challenges in monitoring DAMPs in vivo, and the obvious limitations of the nude mouse model used in this study, particularly with respect to the inability to examine immune effector cell infiltration, it is tempting to speculate that the ICD observed in our study may explain the previously reported favorable alteration of the tumor immune microenvironment observed in syngeneic lung carcinoma models on bemcentinib treatment.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7397559\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7397559/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8880942269527965, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"417|428\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"392|406\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0005138"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7397559"],["score","0.8880942269527965"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:7830dbf2d0d5927ddf6c59f013aad5cf625bf6444cf256e60986952e202f3e17"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0002714",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","d9e5d1ee5d960b1da5d78286577c6bbcb400ce27c92653048d04d2ed97ee3768"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9461246763759953, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8122870\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:07d9728d06f1489faaf5a2aac7a5f698fd116dfd6c23565c7291ca341395b224\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/07d9728d06f1489faaf5a2aac7a5f698fd116dfd6c23565c7291ca341395b224\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The most advanced AXL-selective inhibitor, bemcentinib, is currently undergoing phase II clinical trials for NSCLC, pancreas cancer, brain and central nervous system tumors, and mesothelioma (NCT03184571, NCT03649321, NCT03965494, and NCT03654833, respectively).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8122870\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8122870/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9461246763759953, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"43|54\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"143|172\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0002714"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8122870"],["score","0.9461246763759953"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:07d9728d06f1489faaf5a2aac7a5f698fd116dfd6c23565c7291ca341395b224"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","HP:0001744",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","d2e33389050767f97961fa26403040ba7509693e3fcbe05689a47382edeb37f2"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 3, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.3642911835152056, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8357258\", \"PMC:8357258\", \"PMC:8357258\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:6e74300cd840a92a2b664765d7e8ac86264450cf614f53e1a37e2c76ffd97f7c\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/6e74300cd840a92a2b664765d7e8ac86264450cf614f53e1a37e2c76ffd97f7c\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Despite the aggressive systemic BaF3-EpoR-JAK2V617F model with mean overall survival of merely 20 days in the control group, significant survival advantages and reduction of splenomegaly were achieved with bemcentinib.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.3655544435225144, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"206|217\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"174|186\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:295835c56d59239b8f7f870ee005d24d6fe0c0d5618496d80822654d4ef0c6e2\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/295835c56d59239b8f7f870ee005d24d6fe0c0d5618496d80822654d4ef0c6e2\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Moreover, combination treatment with bemcentinib and ruxolitinib showed additive effects on survival and splenomegaly.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.3654519081064413, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"37|48\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"105|117\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:3d531df13a03c112ed5b6c485546001ff81b7a48a8647b1bd66350d904e5fefb\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/3d531df13a03c112ed5b6c485546001ff81b7a48a8647b1bd66350d904e5fefb\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Vehicle-treated mice presented with splenomegaly, which was significantly reduced in bemcentinib- as well as ruxolitinib-treated mice compared with vehicle-treated mice.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.3618671989166609, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"85|96\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"36|48\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","4"],["object","HP:0001744"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8357258|PMC:8357258|PMC:8357258"],["score","1.3642911835152056"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:6e74300cd840a92a2b664765d7e8ac86264450cf614f53e1a37e2c76ffd97f7c|tmkp:295835c56d59239b8f7f870ee005d24d6fe0c0d5618496d80822654d4ef0c6e2|tmkp:3d531df13a03c112ed5b6c485546001ff81b7a48a8647b1bd66350d904e5fefb"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0011996",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","d0f8979fd6ee77aabce98e6cc5256f956eedaac41b3466e856da98f916cd3a11"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.019879968849511, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8357258\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:cd2192347f2e7c6bbe4194178682f2a37260a4cb88012c38167218fa339cc1e0\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/cd2192347f2e7c6bbe4194178682f2a37260a4cb88012c38167218fa339cc1e0\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Furthermore, we demonstrated GAS6-AXL signaling in chronic myeloid leukemia (CML) cell lines and patient samples and showed growth inhibition of CML cells by bemcentinib.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.019879968849511, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"158|169\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"145|148\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0011996"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8357258"],["score","1.019879968849511"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:cd2192347f2e7c6bbe4194178682f2a37260a4cb88012c38167218fa339cc1e0"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0011282",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","c82ea4dc8f18b3edc6d92894bf3ae6422b84c226ac888faade371c2ceb956729"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.3917344825249667, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8547516\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:c731f8a275a8ea7645c859929577d3e7acee4dd96148a82c91f62627b00f22ac\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/c731f8a275a8ea7645c859929577d3e7acee4dd96148a82c91f62627b00f22ac\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The highest-scoring candidate bemcentinib (DB12411, ?10.4 kcal/mol) is an experimental selective inhibitor of AXL kinase and currently being tested in phase II clinical trials for nonsmall-cell lung cancer and triple-negative breast cancer.?\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8547516\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8547516/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.3917344825249667, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"30|41\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"180|205\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0011282"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8547516"],["score","1.3917344825249667"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:c731f8a275a8ea7645c859929577d3e7acee4dd96148a82c91f62627b00f22ac"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0006047",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","c1c47b3c06d5dc919cb702853c40d6ed6a700a9bd18da9005d9897a9455064e3"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 3, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0467688077103114, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8469858\", \"PMC:7466866\", \"PMC:7595263\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:d9918aa57867dbb58b558b07960c842590e7536a0f5f16e8b56e7bba7cf7f72e\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/d9918aa57867dbb58b558b07960c842590e7536a0f5f16e8b56e7bba7cf7f72e\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib entered clinical trials as the first Axl-specific inhibitor and is undergoing Phase I/II clinical trials for melanoma, non-small-cell lung cancer (NSCLC), mesothelioma, acute myeloid leukemia, glioblastoma, and pancreatic adenocarcinoma (Clinical Trial Identification Numbers: NCT02872259; NCT02922777; NCT03184571; NCT03654833; NCT03824080; NCT03965494; NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8469858\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8469858/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0471877841942248, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"223|248\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:d17fbc4b51a2ba5e33db62f2e0e5ffa6658d30c965cc7192639882a0dfd43fa2\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/d17fbc4b51a2ba5e33db62f2e0e5ffa6658d30c965cc7192639882a0dfd43fa2\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Following encouraging results from a pre-clinical trial, bemcentinib (BGB324), an oral Axl inhibitor, is currently being tested in a multicenter, randomized, phase 1b/2 clinical trial in advanced PDAC.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7466866\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7466866/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0468747044008104, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"57|68\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"196|200\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:e0fc1a55ec85ba0bc55e7c0a686493e95b32010ef6809390ab129ff9eae5bd6f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/e0fc1a55ec85ba0bc55e7c0a686493e95b32010ef6809390ab129ff9eae5bd6f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"These findings led to a multicenter, randomized, phase Ib/II clinical trial of nab-paclitaxel/gemcitabine/cisplatin with or without bemcentinib is in progress in patients with metastatic PDAC.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7595263\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7595263/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0462439345358991, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"132|143\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"187|191\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","3"],["object","MONDO:0006047"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8469858|PMC:7466866|PMC:7595263"],["score","1.0467688077103114"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:d9918aa57867dbb58b558b07960c842590e7536a0f5f16e8b56e7bba7cf7f72e|tmkp:d17fbc4b51a2ba5e33db62f2e0e5ffa6658d30c965cc7192639882a0dfd43fa2|tmkp:e0fc1a55ec85ba0bc55e7c0a686493e95b32010ef6809390ab129ff9eae5bd6f"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005105",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","b9a128147299d9e7d60e421c06c39d0de135f2c075a824126b091549bebbcd11"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 5, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8746840837378628, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8469858\", \"PMC:8997563\", \"PMC:8357258\", \"PMC:8992561\", \"PMC:8652404\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5079935eb46a73a51d8bc45e739cf308f8f671feeedc4b75120be12841e1fddb\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5079935eb46a73a51d8bc45e739cf308f8f671feeedc4b75120be12841e1fddb\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib entered clinical trials as the first Axl-specific inhibitor and is undergoing Phase I/II clinical trials for melanoma, non-small-cell lung cancer (NSCLC), mesothelioma, acute myeloid leukemia, glioblastoma, and pancreatic adenocarcinoma (Clinical Trial Identification Numbers: NCT02872259; NCT02922777; NCT03184571; NCT03654833; NCT03824080; NCT03965494; NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8469858\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8469858/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8747916454507866, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"121|129\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:4221928da0be0822d190d657c8d0fc5d41cf0cc91d20361948f5ed7b87f24f0b\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/4221928da0be0822d190d657c8d0fc5d41cf0cc91d20361948f5ed7b87f24f0b\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"For instance, bemcentinib was investigated in combination with either dabrafenib/trametinib (D/T) or IC pembrolizumab in melanoma patients.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8997563\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8997563/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"CONCL\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8747728612774252, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"14|25\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"121|129\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:94e6a5b8221b7598b2409c210ad9df6be239ba540303989d490edebafb489964\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/94e6a5b8221b7598b2409c210ad9df6be239ba540303989d490edebafb489964\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Currently, bemcentinib is studied in combination with chemotherapy, immunotherapy, or targeted therapies in non-small cell lung cancer (NCT03184571, NCT02922777, NCT02424617), triple negative breast cancer (NCT03184558), pancreatic cancer (NCT03649321), glioblastoma (NCT03965494), malignant mesothelioma (NCT03654833), and melanoma (NCT02872259).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8747059525070735, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"11|22\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"324|332\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:e146cc89ad149cf0d681c508cbf7350926390db21e335ed6a8e64c5c71084eba\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/e146cc89ad149cf0d681c508cbf7350926390db21e335ed6a8e64c5c71084eba\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib is currently in phase II development for a variety of malignancies including NSCLC (NCT03184571), mesothelioma (NCT03654833), triple-negative breast cancer (NCT03184558), and melanoma (NCT02872259) in combination with pembrolizumab.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8992561\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8992561/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8746356650363873, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"187|195\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:0c0c62de057936c34661ea8536c15bf445e6a781bd2cf0e114136e3281ce92a6\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/0c0c62de057936c34661ea8536c15bf445e6a781bd2cf0e114136e3281ce92a6\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Based on these findings, bemcentinib is currently being tested in phase 2?clinical trials for various types of cancers such as melanoma, NSCSC, pancreatic, and AML (Zhu et al.,).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8745142944176411, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"25|36\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"127|135\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","4"],["object","MONDO:0005105"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8469858|PMC:8997563|PMC:8357258|PMC:8992561|PMC:8652404"],["score","0.8746840837378628"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:5079935eb46a73a51d8bc45e739cf308f8f671feeedc4b75120be12841e1fddb|tmkp:4221928da0be0822d190d657c8d0fc5d41cf0cc91d20361948f5ed7b87f24f0b|tmkp:94e6a5b8221b7598b2409c210ad9df6be239ba540303989d490edebafb489964|tmkp:e146cc89ad149cf0d681c508cbf7350926390db21e335ed6a8e64c5c71084eba|tmkp:0c0c62de057936c34661ea8536c15bf445e6a781bd2cf0e114136e3281ce92a6"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0018881",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","b15daeff767500ca6964a5de543417e79400923979bf3af9fc92e74767817315"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 6, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9587352734566725, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8324480\", \"PMC:8324480\", \"PMC:8357258\", \"PMC:6679203\", \"PMC:9261311\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:f601976cae887c179037aca6d799946360bd83e6c9263ba3530788c037fabc28\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/f601976cae887c179037aca6d799946360bd83e6c9263ba3530788c037fabc28\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Preliminary results from this study showed bemcentinib was well tolerated in patients with MDS and had a response rate of 33%.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8324480\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8324480/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.958814680655526, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"43|54\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"91|94\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:3d50324900afb1b7ae47a7b6ea55bd55e3fca2a80ddf830ad9047aa4180ed66f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/3d50324900afb1b7ae47a7b6ea55bd55e3fca2a80ddf830ad9047aa4180ed66f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Finally, bemcentinib is a highly selective inhibitor of the AXL receptor tyrosine kinase that is being investigated in a phase 2 study in patients with higher-risk MDS or AML who failed or were refractory to first-line HMA treatment (NCT03824080).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8324480\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8324480/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9587703587521405, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"9|20\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"164|167\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:805124c81418ed2d2f820f9c5cf3f98add73cf11545912295f528738f3d2ff12\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/805124c81418ed2d2f820f9c5cf3f98add73cf11545912295f528738f3d2ff12\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib represents a well-tolerated, specific AXL inhibitor with clinical activity in AML and is currently under investigation in a phase 2 trial in AML and myelodysplastic syndrome (NCT03824080).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9587559301498262, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"161|185\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:20ad07713181b1f49937a0761f845dc4a5bfe9710387071749080c64d41a3e91\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/20ad07713181b1f49937a0761f845dc4a5bfe9710387071749080c64d41a3e91\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6679203\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6679203/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"reference\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9587078380066072, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"33|44\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"164|188\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:6938514202e1f3cd6b96739ff52adaa4b56a62cc5a5dbb2f16e7447afb8a22f9\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/6938514202e1f3cd6b96739ff52adaa4b56a62cc5a5dbb2f16e7447afb8a22f9\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Several new therapies are being evaluated in clinical trials for their clinical impact potential for high-risk adult MDS patients, including new generation HMAs, isocitrate dehydrogenase inhibitors, the Hedgehog pathway inhibitor glasdegib, venetoclax plus azacitidine, CPX-351, the anti-CD47 monoclonal antibody magrolimab and the NEDD8 inhibitor pevonedistat, both in combination with azacitidine, and kinase inhibitors such as rigosertib, midostaurin, gilteritinib, and bemcentinib.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9261311\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9261311/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9586275597192631, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"473|484\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"117|120\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0018881"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8324480|PMC:8324480|PMC:8357258|PMC:6679203|PMC:9261311"],["score","0.9587352734566725"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:f601976cae887c179037aca6d799946360bd83e6c9263ba3530788c037fabc28|tmkp:3d50324900afb1b7ae47a7b6ea55bd55e3fca2a80ddf830ad9047aa4180ed66f|tmkp:805124c81418ed2d2f820f9c5cf3f98add73cf11545912295f528738f3d2ff12|tmkp:20ad07713181b1f49937a0761f845dc4a5bfe9710387071749080c64d41a3e91|tmkp:6938514202e1f3cd6b96739ff52adaa4b56a62cc5a5dbb2f16e7447afb8a22f9"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0040679",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","abf416604128ff3d44373ed9047f40a2e4ae96b896b50e3129a6caeaec2df501"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.975226977767185, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8992561\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:9abee8238db9278a822b03fa3aba7b05ddef7f91730f023a4c3fa1b00f4412f7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/9abee8238db9278a822b03fa3aba7b05ddef7f91730f023a4c3fa1b00f4412f7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Phase II ICB combination trials of both bemcentinib (NCT03184571) and sitravatinib (NCT02954991) in ICB-refractory NSCLC have shown promising results compared to salvage chemotherapy benchmarks, and have allowed the advancement of sitravatinib to a phase III randomized trial vs. docetaxel (NCT03906071) and also to a phase II trial in ICB-refractory urothelial carcinoma (NCT03606174).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8992561\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8992561/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.975226977767185, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"40|51\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"351|371\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0040679"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8992561"],["score","0.975226977767185"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:9abee8238db9278a822b03fa3aba7b05ddef7f91730f023a4c3fa1b00f4412f7"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005233",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","aa8ba2e3f296ba7deca916f529203e2fa29059f0af9c23bed251c79cafac24c7"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 47, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9241562042500421, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7254113\", \"PMC:8541586\", \"PMC:9040166\", \"PMC:7015993\", \"PMC:9058057\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:2e71bc16a4e3f1fe07ee51568cc36fc12497fa078e684da1f97c9ee336321364\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/2e71bc16a4e3f1fe07ee51568cc36fc12497fa078e684da1f97c9ee336321364\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"These include BGB324/bemcentinib (BergenBio) in NSCLC (clinicaltrials.gov\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7254113\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7254113/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9242082524837263, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"21|32\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"48|53\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:93974c217ba89abd26bc082859ea2dcdbd21f5a3164dc928f7439dab99bc28ef\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/93974c217ba89abd26bc082859ea2dcdbd21f5a3164dc928f7439dab99bc28ef\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib (DB12411 an investigational drug for the treatment of non-small cell lung cancer) (Figure S1A,E) showed the highest binding energy, ?10.2 kcal/mol, with the SARS-CoV-2 Mpro (Table 1).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8541586\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8541586/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9241882801645296, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"66|92\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:075a1000cd5f17694443b6f158bb57d20f72e56f1139d9b9d7bba22eb2995af9\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/075a1000cd5f17694443b6f158bb57d20f72e56f1139d9b9d7bba22eb2995af9\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"These results suggest that STK11/LKB1 mutant NSCLC individuals express AXL in their TME, which has the potential to serve as a biomarker for evaluating combination therapy with bemcentinib and PD-1 inhibitors.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9040166\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9040166/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9241419554797264, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"177|188\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"45|50\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:35f48f2de3cb9f7c618ae387f568a2e14f2e531df2e9dbf142273622703b1808\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/35f48f2de3cb9f7c618ae387f568a2e14f2e531df2e9dbf142273622703b1808\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"With its prominent oncogenic roles, AXL has been proposed as a therapeutic target for TNBC and also for other cancers, and one of its selective inhibitors R428 (BGB324; Bemcentinib) is under clinical trials for acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) (NCT02488408/NCT02424617) as well as for advanced TNBC and adenocarcinoma of the lung in combination with pembrolizumab.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7015993\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7015993/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9241216595349871, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"169|180\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"241|267\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:ad2e17e0d72656d797750f9e824721d151b7c6a60c2eef4555548a5eaa243d1c\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/ad2e17e0d72656d797750f9e824721d151b7c6a60c2eef4555548a5eaa243d1c\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib, which is orally bioavailable and currently in Phase 2 trials for non-small-cell lung cancer, may deter SARS-CoV-2 cellular entry via inhibition of PS receptors.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9058057\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9058057/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.924120873587241, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"78|104\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0005233"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7254113|PMC:8541586|PMC:9040166|PMC:7015993|PMC:9058057"],["score","0.9241562042500421"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:2e71bc16a4e3f1fe07ee51568cc36fc12497fa078e684da1f97c9ee336321364|tmkp:93974c217ba89abd26bc082859ea2dcdbd21f5a3164dc928f7439dab99bc28ef|tmkp:075a1000cd5f17694443b6f158bb57d20f72e56f1139d9b9d7bba22eb2995af9|tmkp:35f48f2de3cb9f7c618ae387f568a2e14f2e531df2e9dbf142273622703b1808|tmkp:ad2e17e0d72656d797750f9e824721d151b7c6a60c2eef4555548a5eaa243d1c"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0004992",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","aa8464032ec2c19b6d9e75c3fb94ab469db193054c4bbe575f6b401248a8b258"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 19, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.37235649232635054, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:6536582\", \"PMC:7291090\", \"PMC:8948193\", \"PMC:7998716\", \"PMC:7601762\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:1eafa9eb9ab4f56b0016dbb709bf3d6883a0444e01ac7cfb4abc6783c6aa9f1f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/1eafa9eb9ab4f56b0016dbb709bf3d6883a0444e01ac7cfb4abc6783c6aa9f1f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"AXL RTK is thus an important therapeutic target in cancer and the small molecule bemcentinib, a selective AXL RTK inhibitor (formerly called BGB324), is currently in phase II clinical trials for e.g.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6536582\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6536582/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.3723763614571851, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"81|92\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"51|57\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:46227e55af0fba293cdc1e5fe67d04522013e551e35895b44906b9154a8e5acf\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/46227e55af0fba293cdc1e5fe67d04522013e551e35895b44906b9154a8e5acf\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib was recently shown to block lysosomal acidification and promote the accumulation of autophagosomes in cancer cells independently of its inhibitory effects on AXL, thereby suggesting an additional overlapping mechanism with the above-mentioned lysosomotropic agents.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7291090\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7291090/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.37236056569561865, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"114|120\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:8a856b785b4f78712b5dc41ee60c0a3f1da70307be051ebcc478523f601d8866\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/8a856b785b4f78712b5dc41ee60c0a3f1da70307be051ebcc478523f601d8866\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"BGB324 (R428, bemcentinib) is a highly potent new anti-cancer compound that blocks AXL autophosphorylation, leading to inhibition of cancer cell proliferation, invasion and metastasis.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8948193\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8948193/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.3723508907916592, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"14|25\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"133|139\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:a7aa7937b050e8adfb488acbd8d30e58d973004cdea6c7c377c1713adc3eb7b1\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/a7aa7937b050e8adfb488acbd8d30e58d973004cdea6c7c377c1713adc3eb7b1\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Increased autophagic flux was also observed upon treatment of renal cancer cells with bemcentinib.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7998716\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7998716/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.3723485698578253, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"86|97\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"68|74\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:009453917309180ecb57b3e7a8b1a8f4d719af0c50ba35aaca20458c0b23f486\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/009453917309180ecb57b3e7a8b1a8f4d719af0c50ba35aaca20458c0b23f486\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In this context, it is interesting to note that the AXL inhibitor Bemcentinib (BGB324), currently undergoing Phase II clinical trials for several cancer types, has been fast-tracked towards Phase II clinical trials by the UK government-funded ACCORD (Accelerating Covid-19 Research & Development platform) study, while other AXL inhibitors have been proposed as possible treatments for COVID-19.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7601762\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7601762/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.3723460738294645, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"66|77\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"146|152\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0004992"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:6536582|PMC:7291090|PMC:8948193|PMC:7998716|PMC:7601762"],["score","0.37235649232635054"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:1eafa9eb9ab4f56b0016dbb709bf3d6883a0444e01ac7cfb4abc6783c6aa9f1f|tmkp:46227e55af0fba293cdc1e5fe67d04522013e551e35895b44906b9154a8e5acf|tmkp:8a856b785b4f78712b5dc41ee60c0a3f1da70307be051ebcc478523f601d8866|tmkp:a7aa7937b050e8adfb488acbd8d30e58d973004cdea6c7c377c1713adc3eb7b1|tmkp:009453917309180ecb57b3e7a8b1a8f4d719af0c50ba35aaca20458c0b23f486"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0004970",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","a7cc16cb9f9f4cbac31cb0f514d818cb86f12dbc06353eb94d38e1f2225a937e"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7480366806155766, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7696061\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:12f5400c21413d57d3815d910b50d9e1c08c2057c8cda29fd823cde475f1ee53\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/12f5400c21413d57d3815d910b50d9e1c08c2057c8cda29fd823cde475f1ee53\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"BGB324 (Bemcentinib or R428) is probably the most selective AXL inhibitor and, recently, in combination with pembrolizumab, was implicated in clinical trials for triple-negative breast cancer (TNBC) and adenocarcinoma.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7696061\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7696061/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7480366806155766, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"8|19\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"203|217\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0004970"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7696061"],["score","0.7480366806155766"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:12f5400c21413d57d3815d910b50d9e1c08c2057c8cda29fd823cde475f1ee53"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0007254",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","174830856787bc0b3d0f0e977955a69cc3e82518c472b92c2d118ab15ae4bea1"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7619132062900146, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9157040\", \"PMC:8282443\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:b4203333bb09e9bb1884efefcfdc9e983ddd193db283ee9064533aec21d1aa66\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/b4203333bb09e9bb1884efefcfdc9e983ddd193db283ee9064533aec21d1aa66\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"R428 (bemcentinib) is a selective Axl inhibitor with a half-maximal inhibitory concentration of 14?nM, which could suppress breast cancer metastasis, angiogenesis and inflammatory cytokine production by inhibiting Axl and downstream Akt phosphorylation.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9157040\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9157040/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7619349152095564, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"6|17\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"124|137\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:043c391d39a56b6b09de5dde82c3c5314c8c62ed2467fac726230a9a24d347a7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/043c391d39a56b6b09de5dde82c3c5314c8c62ed2467fac726230a9a24d347a7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib, a highly selective and potent inhibitor of AXL, is currently being tested in phase 2 trials in various malignancies, including NSCLC, acute myeloid leukemia, and breast cancer.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8282443\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8282443/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7618914973704728, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"175|188\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0007254"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9157040|PMC:8282443"],["score","0.7619132062900146"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:b4203333bb09e9bb1884efefcfdc9e983ddd193db283ee9064533aec21d1aa66|tmkp:043c391d39a56b6b09de5dde82c3c5314c8c62ed2467fac726230a9a24d347a7"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005192",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","0fc23de3232450d393a65359f98473eaa60dc7f4b63469598e1f3ffc2402cf75"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 12, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9427339125284006, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7913382\", \"PMC:7408754\", \"PMC:8349827\", \"PMC:8179919\", \"PMC:8357258\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:19fb7fd04a538de8a3e8710131ad78ef20b03307cb3c558342d63bb1e80eeff8\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/19fb7fd04a538de8a3e8710131ad78ef20b03307cb3c558342d63bb1e80eeff8\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In this context, bemcentinib, also known as BGB324 or R428, has been investigated in clinical trials for the treatment of pancreatic cancer.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7913382\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7913382/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9428160481318203, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"17|28\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"122|139\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:9f78f01d3097a6e48e0a661f07f0756aac3aca54b5d9ed49d5b0c68e07386a76\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/9f78f01d3097a6e48e0a661f07f0756aac3aca54b5d9ed49d5b0c68e07386a76\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Similarly, in murine pancreatic cancer models, bemcentinib decreased tumor infiltrating macrophages.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7408754\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7408754/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9427705052829929, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"46|57\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"20|37\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:a70bb88bce6713d91051777bd31a0387ffa085fa0638c0bc8b5f592c3d4fe680\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/a70bb88bce6713d91051777bd31a0387ffa085fa0638c0bc8b5f592c3d4fe680\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The efficacy of bemcentinib in combination with chemotherapy is being tested currently in pancreatic cancer patients (NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8349827\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8349827/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9427688167639497, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"16|27\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"90|107\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:653c20214054a777609e8462df96f61270347b115fb3c0b1872769b3d9d9688f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/653c20214054a777609e8462df96f61270347b115fb3c0b1872769b3d9d9688f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib (BGB324), a specific type I kinase inhibitor of Axl with promising preclinical results has entered clinical trials for cancers including non-small cell lung carcinoma, adenocarcinoma of the lung, acute myeloid leukemia, melanoma and pancreatic cancer (obtained from ClinicalTrials.gov).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8179919\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8179919/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9426575443023157, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"245|262\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:ff14b23046b91c1cfe32eb28a76b0d566ad211c3f96360109e7986f739e11522\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/ff14b23046b91c1cfe32eb28a76b0d566ad211c3f96360109e7986f739e11522\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Currently, bemcentinib is studied in combination with chemotherapy, immunotherapy, or targeted therapies in non-small cell lung cancer (NCT03184571, NCT02922777, NCT02424617), triple negative breast cancer (NCT03184558), pancreatic cancer (NCT03649321), glioblastoma (NCT03965494), malignant mesothelioma (NCT03654833), and melanoma (NCT02872259).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9426566481609242, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"11|22\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"221|238\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0005192"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7913382|PMC:7408754|PMC:8349827|PMC:8179919|PMC:8357258"],["score","0.9427339125284006"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:19fb7fd04a538de8a3e8710131ad78ef20b03307cb3c558342d63bb1e80eeff8|tmkp:9f78f01d3097a6e48e0a661f07f0756aac3aca54b5d9ed49d5b0c68e07386a76|tmkp:a70bb88bce6713d91051777bd31a0387ffa085fa0638c0bc8b5f592c3d4fe680|tmkp:653c20214054a777609e8462df96f61270347b115fb3c0b1872769b3d9d9688f|tmkp:ff14b23046b91c1cfe32eb28a76b0d566ad211c3f96360109e7986f739e11522"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0007576",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","97cc645ff2bdda7f193c31cff3af17b46adf28f8b88320548f24aa60d7df66a5"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9758940619231549, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8652404\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:87d0629f4b842f79aa1fdbc375b67b07abe2852e7d3864e7142c5213640e3670\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/87d0629f4b842f79aa1fdbc375b67b07abe2852e7d3864e7142c5213640e3670\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In particular, bemcentinib, a highly selective small molecule AXL inhibitor, was shown to block tumor growth in AXL?expressing metastatic breast and esophageal cancer models (Holland et al.,; Yang et al.,).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9758940619231549, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"15|26\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"149|166\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0007576"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8652404"],["score","0.9758940619231549"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:87d0629f4b842f79aa1fdbc375b67b07abe2852e7d3864e7142c5213640e3670"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005057",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","96ffe1aa87f51d8950f5a7cf2b8a857709b14f7b4e7e4e270d737f4a64933542"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.213927774051761, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7925356\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:006321b18c866df53c6905fcb92b377f78878bc50cb9e1c5eb00642d03ebbfc7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/006321b18c866df53c6905fcb92b377f78878bc50cb9e1c5eb00642d03ebbfc7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"We also examined the effects of AXL inhibition with the selective small-molecule AXL inhibitor BGB324 (bemcentinib) and AXL knockdown on DNA damage and RS in NSCLC and LCNEC cells.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7925356\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7925356/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.213927774051761, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"103|114\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"168|173\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0005057"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7925356"],["score","1.213927774051761"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:006321b18c866df53c6905fcb92b377f78878bc50cb9e1c5eb00642d03ebbfc7"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0011719",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","954e30518f6d62dc80e4728ccf27201b1c3b15b73182701f53f4cac5652dfa83"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.100184241518384, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8492542\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:2a2b191138d4d24905b9b3d5cac44781a77b42e90fef8b76499f1081b2a68e3e\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/2a2b191138d4d24905b9b3d5cac44781a77b42e90fef8b76499f1081b2a68e3e\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"We evaluated these targets in vitro and found that primary imatinib-resistant GIST cells were effectively targeted with either single agent bemcentinib (AXL inhibitor) or bardoxolone (NF-?B inhibitor), as well as with either agent in combination with imatinib.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8492542\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8492542/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.100184241518384, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"140|151\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"78|82\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0011719"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8492542"],["score","1.100184241518384"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:2a2b191138d4d24905b9b3d5cac44781a77b42e90fef8b76499f1081b2a68e3e"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0002280",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","8dafecdcde0661e7ca3ef7aab54f7c31dcd3434a6d5f8196f1d273f390d752e9"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7964531175598609, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8357258\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:62ca4926a1b03a320231f10ff001e7a18ff85f9d68297d28d3f11eda673f234a\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/62ca4926a1b03a320231f10ff001e7a18ff85f9d68297d28d3f11eda673f234a\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Beyond that, bemcentinib showed to positively impact erythropoiesis and alleviate anemia in vivo.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8357258\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8357258/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7964531175598609, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"13|24\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"82|88\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0002280"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8357258"],["score","0.7964531175598609"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:62ca4926a1b03a320231f10ff001e7a18ff85f9d68297d28d3f11eda673f234a"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0008170",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","889e692d241a932f2d56388ef51bd016d93a9aa19d0cfee460f24613fdc52e55"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8787213885828362, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8703923\", \"PMC:6896070\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:b7d06cdac88b336ba2eab2d60587217c14377e20862de5ed3eee039ab46badcc\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/b7d06cdac88b336ba2eab2d60587217c14377e20862de5ed3eee039ab46badcc\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In parallel, combined treatment with VS-6766/CH5126766 and AXL inhibitor (bemcentinib) has provided a stronger blockage of tumor growth in KRAS-mutant ovarian cancer cells with overexpressed AXL.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8703923\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8703923/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8796802733737371, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"74|85\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"151|165\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:f7037146ec588495da1a49ba7db0ce0df3bdd57012c2661e2ce5e2717905b0e7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/f7037146ec588495da1a49ba7db0ce0df3bdd57012c2661e2ce5e2717905b0e7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"AXL inhibition by BGB324 (R428/Bemcentinib) increased response to chemotherapy in a patient-derived xenograft model from a chemoresistant ovarian cancer.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6896070\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6896070/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.8777625037919352, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"31|42\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"138|152\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0008170"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8703923|PMC:6896070"],["score","0.8787213885828362"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:b7d06cdac88b336ba2eab2d60587217c14377e20862de5ed3eee039ab46badcc|tmkp:f7037146ec588495da1a49ba7db0ce0df3bdd57012c2661e2ce5e2717905b0e7"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005494",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","879f9fd8e90a3a38c58716da459f31f4ec91d468412568d8981bdc658cb210bc"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 19, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0910121479184502, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9092944\", \"PMC:7696061\", \"PMC:8469858\", \"PMC:8547516\", \"PMC:8833442\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:bb9785a41e25d859e424376d54cf6f88b4cfcf8dd74265708cf828ff20e41dbc\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/bb9785a41e25d859e424376d54cf6f88b4cfcf8dd74265708cf828ff20e41dbc\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Assessment of bemcentinib/pembrolizumab effects in refractory TNBC patients (phase II, NCT03184558) was discontinued as none of the participants achieved a complete or partial response (n=29).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9092944\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9092944/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0910827477474114, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"14|25\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"62|66\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:04c356bfd6fa50728eb9021654edbcc0ff24c0e8d682693f35b8623692e13a59\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/04c356bfd6fa50728eb9021654edbcc0ff24c0e8d682693f35b8623692e13a59\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"BGB324 (Bemcentinib or R428) is probably the most selective AXL inhibitor and, recently, in combination with pembrolizumab, was implicated in clinical trials for triple-negative breast cancer (TNBC) and adenocarcinoma.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7696061\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7696061/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.091017846559353, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"8|19\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"193|197\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:8f402f0675d2b065c37b68119b9dd3b1c4d3ea46bb793805dd5ce387225e0a21\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/8f402f0675d2b065c37b68119b9dd3b1c4d3ea46bb793805dd5ce387225e0a21\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"A Phase II clinical trial of bemcentinib in combination with pembrolizumab for patients with triple-negative breast cancer has been completed, but the results are not yet available (Clinical Trial Identification #: NCT03184558).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8469858\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8469858/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0910148444017893, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"29|40\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"93|122\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:326a7f55b1ef54e6e04f547e0419ec50987bca981f9249d5b9977dc2a81a2484\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/326a7f55b1ef54e6e04f547e0419ec50987bca981f9249d5b9977dc2a81a2484\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The highest-scoring candidate bemcentinib (DB12411, ?10.4 kcal/mol) is an experimental selective inhibitor of AXL kinase and currently being tested in phase II clinical trials for nonsmall-cell lung cancer and triple-negative breast cancer.?\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8547516\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8547516/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.090983294455029, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"30|41\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"210|239\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:1b206d2e38b48b5d2ec6f1eb9a542c2d23bb2ec8a94b0c3a3351b907f2375636\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/1b206d2e38b48b5d2ec6f1eb9a542c2d23bb2ec8a94b0c3a3351b907f2375636\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"A phase II trial of bemcentinib, an oral AXL inhibitor, in combination with pembrolizumab in patients with TNBC and adenocarcinoma of the lung, has completed data collection and results are pending.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8833442\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8833442/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0909620064286685, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"20|31\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"107|111\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0005494"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9092944|PMC:7696061|PMC:8469858|PMC:8547516|PMC:8833442"],["score","1.0910121479184502"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:bb9785a41e25d859e424376d54cf6f88b4cfcf8dd74265708cf828ff20e41dbc|tmkp:04c356bfd6fa50728eb9021654edbcc0ff24c0e8d682693f35b8623692e13a59|tmkp:8f402f0675d2b065c37b68119b9dd3b1c4d3ea46bb793805dd5ce387225e0a21|tmkp:326a7f55b1ef54e6e04f547e0419ec50987bca981f9249d5b9977dc2a81a2484|tmkp:1b206d2e38b48b5d2ec6f1eb9a542c2d23bb2ec8a94b0c3a3351b907f2375636"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0002334",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","850e36db9585e3c957f5059b4852ec25310a1e8d5f7d81824d9c968ccbf1029f"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7125278342755514, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:6718264\", \"PMC:8781146\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5a25416299944dbaa8ddf35d601463f27d97020c168fbdcaac2062645a517ea2\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5a25416299944dbaa8ddf35d601463f27d97020c168fbdcaac2062645a517ea2\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and is currently under investigation in phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics as a forefront runner in development (ClinicalTrials.gov\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6718264\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6718264/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7125478291634842, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"142|162\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:4027008ff8bc16f15ff1a99b789c14b15d648b518f950733bf1b2abf3848e506\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/4027008ff8bc16f15ff1a99b789c14b15d648b518f950733bf1b2abf3848e506\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Therefore, MITF- resistant populations could be targeted with AXL inhibitors, such as bemcentinib, currently in Phase II trials for different solid and hematological tumors.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8781146\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8781146/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7125078393876186, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"86|97\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"152|172\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0002334"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:6718264|PMC:8781146"],["score","0.7125278342755514"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:5a25416299944dbaa8ddf35d601463f27d97020c168fbdcaac2062645a517ea2|tmkp:4027008ff8bc16f15ff1a99b789c14b15d648b518f950733bf1b2abf3848e506"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0100430",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","7057a2a82b0c213dd99b2057f14c22548fc2dd58394c2eb03347838b66997609"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 6, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9995348099999999, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:6536582\", \"PMC:7013198\", \"PMC:7013198\", \"PMC:7013198\", \"PMC:7013198\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:acc01520c2d9a2b2bef1eaa647da7bfd65a38cc8727467e7d4ba81570c65cbd7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/acc01520c2d9a2b2bef1eaa647da7bfd65a38cc8727467e7d4ba81570c65cbd7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"A study on liver fibrosis showed that AXL and GAS6 are required to induce fibrogenesis by hepatic stellate cells; Accordingly, exposition to bemcentinib reduced liver fibrosis in mice.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6536582\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6536582/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9995678, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"141|152\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"161|175\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:011b34211f339fa9b169373398e04c6d431b9dfd52b905ae00a199d8698b3d0d\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/011b34211f339fa9b169373398e04c6d431b9dfd52b905ae00a199d8698b3d0d\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Therefore, the strong induction of liver fibrosis and inflammation observed in mice receiving HFD during 2 months was clearly diminished by bemcentinib administration for the last 2 weeks.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7013198\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7013198/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9995427, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"140|151\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"35|49\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:c2559d09007fe4c02dd0cbe8cba65326f2a147f085d26847c320c9425938c561\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/c2559d09007fe4c02dd0cbe8cba65326f2a147f085d26847c320c9425938c561\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib reduces early liver fibrosis and inflammation in HFD-fed mice.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7013198\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7013198/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9995321, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"26|40\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:9aa230af8666a7117ff8976bfb583a3051d94f90778a612cad7f6dc6797d277c\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/9aa230af8666a7117ff8976bfb583a3051d94f90778a612cad7f6dc6797d277c\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib reduces liver fibrosis and inflammation in HFD-fed mice.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7013198\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7013198/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9995276, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"20|34\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:70db4b4c77ae1f7e3d85bcae3ca78a5d3e306768731fe430cd93aefa5f8794b0\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/70db4b4c77ae1f7e3d85bcae3ca78a5d3e306768731fe430cd93aefa5f8794b0\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib reduced HFD-induced liver fibrosis and inflammation by blocking AXL signaling while increasing GAS6 serum levels.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7013198\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7013198/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.99950385, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"32|46\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0100430"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:6536582|PMC:7013198|PMC:7013198|PMC:7013198|PMC:7013198"],["score","0.9995348099999999"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:acc01520c2d9a2b2bef1eaa647da7bfd65a38cc8727467e7d4ba81570c65cbd7|tmkp:011b34211f339fa9b169373398e04c6d431b9dfd52b905ae00a199d8698b3d0d|tmkp:c2559d09007fe4c02dd0cbe8cba65326f2a147f085d26847c320c9425938c561|tmkp:9aa230af8666a7117ff8976bfb583a3051d94f90778a612cad7f6dc6797d277c|tmkp:70db4b4c77ae1f7e3d85bcae3ca78a5d3e306768731fe430cd93aefa5f8794b0"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005575",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","7009f27b264f949eaf8dfb9f7f51368d829f4313a7548989843e531c3ccfffab"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7815356103961371, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7878213\", \"PMC:7878213\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:012bdb0441f5ebd24887613bc22e30357226eaccfece677599d52609208a325d\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/012bdb0441f5ebd24887613bc22e30357226eaccfece677599d52609208a325d\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Dual treatment with the TGF? galunisertib and the AXL inhibitor, bemcentinib, significantly reduced colony formation and migration capabilities of tumor cells and displayed a strong anti-tumor activity in 3D spheroid cultures derived from patients with advanced CRC.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7878213\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7878213/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7815878371821314, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"65|76\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"262|265\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:c236d02fb2659bce5d082f5f0d566a5b87f338026cd6e4178da5f36194ecc7aa\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/c236d02fb2659bce5d082f5f0d566a5b87f338026cd6e4178da5f36194ecc7aa\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"MTT proliferation assay for colorectal cancer spheroids of case 1?7 treated with 10??M galunisertib and 1??M bemcentinib.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7878213\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7878213/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"fig_caption\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7814833836101428, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"109|120\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"28|45\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0005575"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7878213|PMC:7878213"],["score","0.7815356103961371"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:012bdb0441f5ebd24887613bc22e30357226eaccfece677599d52609208a325d|tmkp:c236d02fb2659bce5d082f5f0d566a5b87f338026cd6e4178da5f36194ecc7aa"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005240",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","626b353d051b7b5659a60300131b02cb2b0f0808c5906ff86dfb3e4ce68f48ca"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.6279707887728705, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8335678\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:a88bb3a00f8da7e3da01f657498f427264735ec6fd0162d7bc9f80e493496622\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/a88bb3a00f8da7e3da01f657498f427264735ec6fd0162d7bc9f80e493496622\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib partially reverses the effects of UUO, without affecting non?ligated kidneys or SHAM?operated mice, and thereby qualifies as a promising treatment in kidney disease.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8335678\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8335678/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.6279707887728705, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"162|176\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0005240"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8335678"],["score","0.6279707887728705"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:a88bb3a00f8da7e3da01f657498f427264735ec6fd0162d7bc9f80e493496622"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0100096",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","606d56f0495552ef45273fabb243cafc4fa91e666ccc40623cb3181d405e59e1"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 4, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9994128175, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9167582\", \"PMC:9167582\", \"PMC:8282443\", \"PMC:8282443\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:8dd2f20609d876f09a642fce40b5f76c8a6bc193e515206f4fd9c1c29914b67f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/8dd2f20609d876f09a642fce40b5f76c8a6bc193e515206f4fd9c1c29914b67f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Currently, several antiviral drugs (e.g.,,?remdesivir, bemcentinib, and lopinavir with ritonavir), immune modulators (e.g.,?azithromycin, brensocatib, anakinra and canakinumab, interferon beta, convalescent plasma, corticosteroids, sarilumab and tocilizumab) are recommended against COVID-19, and their usage mainly depends on patient?s symptoms, while remdesivir is approved by the FDA for treatment of COVID-19.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9167582\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9167582/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.99944276, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"55|66\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"404|412\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:41173f335b8bddcbc6eace5b12dbc036c03531e12834de75ec1f46a672de46e6\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/41173f335b8bddcbc6eace5b12dbc036c03531e12834de75ec1f46a672de46e6\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Currently, several antiviral drugs (e.g.,,?remdesivir, bemcentinib, and lopinavir with ritonavir), immune modulators (e.g.,?azithromycin, brensocatib, anakinra and canakinumab, interferon beta, convalescent plasma, corticosteroids, sarilumab and tocilizumab) are recommended against COVID-19, and their usage mainly depends on patient?s symptoms, while remdesivir is approved by the FDA for treatment of COVID-19.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9167582\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9167582/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.99942005, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"55|66\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"283|291\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:7abe68d69f27938340e98d884ed7361ec78e354a3d5b17ed3f61dbe3df05073d\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/7abe68d69f27938340e98d884ed7361ec78e354a3d5b17ed3f61dbe3df05073d\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"These data support our findings that EMT reversal by bemcentinib may augment the antiviral activity of AXL inhibitors against SARS-CoV-2, resulting in additional clinical benefit for patients with COVID-19.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8282443\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8282443/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.99940896, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"53|64\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"197|205\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:d4d0391a33fcb4dc6def92d5e6857343b020169193bedaaa4f7e7a8187bbdaad\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/d4d0391a33fcb4dc6def92d5e6857343b020169193bedaaa4f7e7a8187bbdaad\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Accordingly, a phase II clinical trial (BGBC020) recently completed accrual of 115 patients, evaluating the efficacy and safety of bemcentinib for the treatment of hospitalized patients with COVID-19 alone or in combination with standard of care.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8282443\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8282443/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9993795, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"131|142\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"191|199\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","4"],["object","MONDO:0100096"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9167582|PMC:9167582|PMC:8282443|PMC:8282443"],["score","0.9994128175"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:8dd2f20609d876f09a642fce40b5f76c8a6bc193e515206f4fd9c1c29914b67f|tmkp:41173f335b8bddcbc6eace5b12dbc036c03531e12834de75ec1f46a672de46e6|tmkp:7abe68d69f27938340e98d884ed7361ec78e354a3d5b17ed3f61dbe3df05073d|tmkp:d4d0391a33fcb4dc6def92d5e6857343b020169193bedaaa4f7e7a8187bbdaad"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005091",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","5a197840177d7267ca5314f93bcf2315228fa1100f2eddc0c52e73d5e74474ad"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 2, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.1307492968584252, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9013431\", \"PMC:9284228\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:1ac3408da889a9fc8c4a532d90e68db8cb51da1a4c8aa03fed072806dfec41b4\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/1ac3408da889a9fc8c4a532d90e68db8cb51da1a4c8aa03fed072806dfec41b4\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"We propose six novel anti-SARS-CoV-2 targets ADCY2, ADSL, OCRL, TIAM1, PBK, and BUB1, and potential drugs targeting these genes, such as Bemcentinib, Phthalocyanine, and Conivaptan.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9013431\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9013431/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.1307492968584252, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"137|148\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"26|30\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5265341d9bd227425a3ca1f7cdcb33a5d4d8f05e019126121ebabd1f105908c2\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5265341d9bd227425a3ca1f7cdcb33a5d4d8f05e019126121ebabd1f105908c2\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"We propose six novel anti-SARS-CoV-2 targets ADCY2, ADSL, OCRL, TIAM1, PBK, and BUB1, and potential drugs targeting these genes, such as Bemcentinib, Phthalocyanine, and Conivaptan.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9284228\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9284228/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.1307492968584252, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"137|148\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"26|30\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","2"],["object","MONDO:0005091"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9013431|PMC:9284228"],["score","1.1307492968584252"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:1ac3408da889a9fc8c4a532d90e68db8cb51da1a4c8aa03fed072806dfec41b4|tmkp:5265341d9bd227425a3ca1f7cdcb33a5d4d8f05e019126121ebabd1f105908c2"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0020320",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","0896b2919ffcab4d2bca51274c9eee0436ab7c76fd46e314834f6c8b02b165c5"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 6, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0071009798753678, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7015993\", \"PMC:8469858\", \"PMC:9135597\", \"PMC:6679203\", \"PMC:8179919\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:857d32dfdc4f58a028e7904cbc11f837e27d0db890972b357b9b7dd6d7261f7c\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/857d32dfdc4f58a028e7904cbc11f837e27d0db890972b357b9b7dd6d7261f7c\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"With its prominent oncogenic roles, AXL has been proposed as a therapeutic target for TNBC and also for other cancers, and one of its selective inhibitors R428 (BGB324; Bemcentinib) is under clinical trials for acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC) (NCT02488408/NCT02424617) as well as for advanced TNBC and adenocarcinoma of the lung in combination with pembrolizumab.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7015993\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7015993/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.007189344323634, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"169|180\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"211|233\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:c21233695a52fc0226f39228ce0ead7bdc8bbfb11511263b112b2355a6e029f3\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/c21233695a52fc0226f39228ce0ead7bdc8bbfb11511263b112b2355a6e029f3\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib entered clinical trials as the first Axl-specific inhibitor and is undergoing Phase I/II clinical trials for melanoma, non-small-cell lung cancer (NSCLC), mesothelioma, acute myeloid leukemia, glioblastoma, and pancreatic adenocarcinoma (Clinical Trial Identification Numbers: NCT02872259; NCT02922777; NCT03184571; NCT03654833; NCT03824080; NCT03965494; NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8469858\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8469858/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0071162850395894, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"181|203\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:9a00ec2388cfaf6c6c8716c4b732fd9279065e7a54a151311437f110f5581453\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/9a00ec2388cfaf6c6c8716c4b732fd9279065e7a54a151311437f110f5581453\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Given this, AXL is a promising therapeutic target, and R428 (bemcentinib), a first-in-class AXL kinase inhibitor, is currently being evaluated in phase 2 clinical trials for metastatic lung and triple-negative breast cancer, glioblastoma, and acute myeloid leukemia.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9135597\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9135597/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0071158819538844, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"61|72\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"243|265\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:df7e248a254ab0d93e33abbb4cae03226da1453d6b46caf928b2af0b5f1f005f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/df7e248a254ab0d93e33abbb4cae03226da1453d6b46caf928b2af0b5f1f005f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:6679203\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC6679203/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"reference\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0070472566125956, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"33|44\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"138|160\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2019, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:cd935c8a956cd94bab3827868acc71f00ebfda87f22a6cfd9ff472f3a7e39e76\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/cd935c8a956cd94bab3827868acc71f00ebfda87f22a6cfd9ff472f3a7e39e76\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib (BGB324), a specific type I kinase inhibitor of Axl with promising preclinical results has entered clinical trials for cancers including non-small cell lung carcinoma, adenocarcinoma of the lung, acute myeloid leukemia, melanoma and pancreatic cancer (obtained from ClinicalTrials.gov).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8179919\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8179919/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0070361314471357, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"208|230\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0020320"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7015993|PMC:8469858|PMC:9135597|PMC:6679203|PMC:8179919"],["score","1.0071009798753678"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:857d32dfdc4f58a028e7904cbc11f837e27d0db890972b357b9b7dd6d7261f7c|tmkp:c21233695a52fc0226f39228ce0ead7bdc8bbfb11511263b112b2355a6e029f3|tmkp:9a00ec2388cfaf6c6c8716c4b732fd9279065e7a54a151311437f110f5581453|tmkp:df7e248a254ab0d93e33abbb4cae03226da1453d6b46caf928b2af0b5f1f005f|tmkp:cd935c8a956cd94bab3827868acc71f00ebfda87f22a6cfd9ff472f3a7e39e76"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005108",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","557e775fb5e342e927b4ba1710f3fd8464a3b125325c37022fc4fd6e8ce70512"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 1, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.742101941525678, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7393340\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:9dfd5b193be902cd2761684d6f963e2c603df3034fb8112b1a2408c394a917aa\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/9dfd5b193be902cd2761684d6f963e2c603df3034fb8112b1a2408c394a917aa\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7393340\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7393340/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"ABSTRACT\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.742101941525678, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"37|52\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","1"],["object","MONDO:0005108"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7393340"],["score","0.742101941525678"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:9dfd5b193be902cd2761684d6f963e2c603df3034fb8112b1a2408c394a917aa"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0004947",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","52d90df5d54e44464e5db6cb5a8e34a15e7388af4eb56952f4df80101d22b475"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 3, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.2114071295114337, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7611942\", \"PMC:7611942\", \"PMC:7611942\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:36be71d83ad2c6a8c0fbbb9e82bae30cda036919da9cc1fa0f2fcbc603e8b95f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/36be71d83ad2c6a8c0fbbb9e82bae30cda036919da9cc1fa0f2fcbc603e8b95f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In the high-risk B-ALL model, single agent treatment with Bemcentinib (Supplementary Fig. S8C) or nilotinib, (Supplementary Fig. S8D), significantly extended survival but all animals eventually succumbed to bona fide B-ALL within 50 days, despite continuous drug treatment.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7611942\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7611942/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.214946431020714, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"58|69\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"17|22\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:0cc133f6adbcd4e408f5e10cca11e95faf248abb0a0999cfd0ddbfd238d616c5\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/0cc133f6adbcd4e408f5e10cca11e95faf248abb0a0999cfd0ddbfd238d616c5\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In light of our work, it would be important to extend such studies to other hematological malignancies such as Ph+ B-ALL, and more specifically evaluate the potential tumor extrinsic immune modulatory function of AXL targeting compounds, including Bemcentinib and other compounds such as Gilteritinib, a dual FLT3/AXL inhibitor that has shown efficacy in FLT3 mutated relapsed or refractory AML \", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7611942\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7611942/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"DISCUSS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.2123949275049835, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"248|259\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"115|120\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:57243e7f315514d9f2320090d8d1f663d5b272f9ea37fd0705d964ea29c06408\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/57243e7f315514d9f2320090d8d1f663d5b272f9ea37fd0705d964ea29c06408\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In the high-risk B-ALL model, single agent treatment with Bemcentinib (Supplementary Fig. S8C) or nilotinib, (Supplementary Fig. S8D), significantly extended survival but all animals eventually succumbed to bona fide B-ALL within 50 days, despite continuous drug treatment.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7611942\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7611942/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.2068800300086036, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"58|69\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"217|222\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","4"],["object","MONDO:0004947"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7611942|PMC:7611942|PMC:7611942"],["score","1.2114071295114337"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:36be71d83ad2c6a8c0fbbb9e82bae30cda036919da9cc1fa0f2fcbc603e8b95f|tmkp:0cc133f6adbcd4e408f5e10cca11e95faf248abb0a0999cfd0ddbfd238d616c5|tmkp:57243e7f315514d9f2320090d8d1f663d5b272f9ea37fd0705d964ea29c06408"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005059",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","078fcd5846b28dc6fde34e7e2ff862b0982987c37f44584c48b2b681c7585472"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 4, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7589145949663239, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:7611942\", \"PMC:7611942\", \"PMC:7611942\", \"PMC:7611942\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:48da139b39e46218c61318449f7fdf437dc2969d460a4340678a66e1ffa93766\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/48da139b39e46218c61318449f7fdf437dc2969d460a4340678a66e1ffa93766\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"To further evaluate whether AXL inhibition may improve overall survival, leukemia bearing mice were first treated with Bemcentinib, as a single agent, on an intermittent schedule of 5 days on, 2 days off for the indicated duration.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7611942\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7611942/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7622927141095522, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"119|130\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"73|81\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:d3d35bac0c283f9209d6d97017a627844321d92bec43d77376300e2d913a9af8\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/d3d35bac0c283f9209d6d97017a627844321d92bec43d77376300e2d913a9af8\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Additionally, when NSG mice, bearing the same leukemia were subjected to combined treatment with nilotinib and Bemcentinib, the latter failed to drastically potentiate nilotinib effects as demonstrated by the fact that 100% of the mice succumbed to leukemia with a median survival that was comparable to nilotinib only treated animals (Fig. 7F).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7611942\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7611942/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7620923902847898, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"111|122\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"46|54\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:5238069e844f22bc9e5baa1c9bf69f6c5fa0c21f91f7cf5a3bbdb991463bde83\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/5238069e844f22bc9e5baa1c9bf69f6c5fa0c21f91f7cf5a3bbdb991463bde83\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Additionally, when NSG mice, bearing the same leukemia were subjected to combined treatment with nilotinib and Bemcentinib, the latter failed to drastically potentiate nilotinib effects as demonstrated by the fact that 100% of the mice succumbed to leukemia with a median survival that was comparable to nilotinib only treated animals (Fig. 7F).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7611942\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7611942/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7619501713525433, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"111|122\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"249|257\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:ff81351f28a05e9fb6e824bcea4d28d68e880bad6c2b9b61cf7d0478b1e74424\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/ff81351f28a05e9fb6e824bcea4d28d68e880bad6c2b9b61cf7d0478b1e74424\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In this study, by using leukemia models that do not express AXL protein (Fig. S2J), we primarily used Bemcentinib to evaluate its potential immune modulatory effects on the non-malignant components of the leukemic microenvironment that express AXL, namely myeloid cells (Fig. 2A).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7611942\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7611942/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.7493231041184102, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"102|113\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"24|32\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","3"],["object","MONDO:0005059"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:7611942|PMC:7611942|PMC:7611942|PMC:7611942"],["score","0.7589145949663239"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:48da139b39e46218c61318449f7fdf437dc2969d460a4340678a66e1ffa93766|tmkp:d3d35bac0c283f9209d6d97017a627844321d92bec43d77376300e2d913a9af8|tmkp:5238069e844f22bc9e5baa1c9bf69f6c5fa0c21f91f7cf5a3bbdb991463bde83|tmkp:ff81351f28a05e9fb6e824bcea4d28d68e880bad6c2b9b61cf7d0478b1e74424"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005086",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","075c159fe62ad996672ba2ab181e1e90cb0128a3c8d07122322f88e6a8b148af"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 10, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9170683573386975, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:8652404\", \"PMC:8652404\", \"PMC:8652404\", \"PMC:8652404\", \"PMC:8652404\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:4c325ca786e82efac990d244772a19cd37b14ae6217d736314bdfe0aa8499470\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/4c325ca786e82efac990d244772a19cd37b14ae6217d736314bdfe0aa8499470\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In the subsequent more extended second study, we tested the effects of bemcentinib and tilvestamab on orthotopic RCC growth in comparison with sunitinib, a well?characterized multi?target tyrosine kinase inhibitor, widely used in human RCC treatment (Ljungberg et al.,).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.917107024485036, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"71|82\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"113|116\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:3402308c5415834209d7597cbf853195639408007e0b91691373886816792dfc\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/3402308c5415834209d7597cbf853195639408007e0b91691373886816792dfc\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"We found that AXL?targeted agents bemcentinib and tilvestamab effectively inhibit AXL activation in vitro and RCC cells growth in an orthotopic implanted mice model.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9170986465115663, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"34|45\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"110|113\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:1025b93030d882612938119057106164a9067ff9cb907a6869523688ed3bb11f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/1025b93030d882612938119057106164a9067ff9cb907a6869523688ed3bb11f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In the subsequent more extended second study, we tested the effects of bemcentinib and tilvestamab on orthotopic RCC growth in comparison with sunitinib, a well?characterized multi?target tyrosine kinase inhibitor, widely used in human RCC treatment (Ljungberg et al.,).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9170710533393607, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"71|82\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"236|239\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:18916a095d0712d8740fe2de7ca796b91748163d003df72ab52133238208aab7\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/18916a095d0712d8740fe2de7ca796b91748163d003df72ab52133238208aab7\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"As depicted in Figure 5, bioluminescence data show that bemcentinib, tilvestamab, and sunitinib significantly inhibited RCC growth down to about 1/3 of the volume, as compared to untreated or control IgG?treated animals (p?<?0.002).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"RESULTS\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9170423681859471, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"56|67\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"120|123\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:73976f91ec18b8a1038eb603397fe8452b3f35b12f146cc69a2b8805a886c736\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/73976f91ec18b8a1038eb603397fe8452b3f35b12f146cc69a2b8805a886c736\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib and tilvestamab qualify as compounds of potentially high clinical interest in AXL overexpressing RCC.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8652404\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8652404/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"ABSTRACT\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 0.9170226941715778, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"109|112\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0005086"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:8652404|PMC:8652404|PMC:8652404|PMC:8652404|PMC:8652404"],["score","0.9170683573386975"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:4c325ca786e82efac990d244772a19cd37b14ae6217d736314bdfe0aa8499470|tmkp:3402308c5415834209d7597cbf853195639408007e0b91691373886816792dfc|tmkp:1025b93030d882612938119057106164a9067ff9cb907a6869523688ed3bb11f|tmkp:18916a095d0712d8740fe2de7ca796b91748163d003df72ab52133238208aab7|tmkp:73976f91ec18b8a1038eb603397fe8452b3f35b12f146cc69a2b8805a886c736"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005065",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","045813ba99b83c2cc183a75025ef5e36b4555131a5ff2a5516c785d5b7430719"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 3, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0375144380225156, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9092944\", \"PMC:8469858\", \"PMC:8992561\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:bd4521ba459bd717eb439c56b59979b8fb44ace89f6ea004205f33c40c88d34f\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/bd4521ba459bd717eb439c56b59979b8fb44ace89f6ea004205f33c40c88d34f\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In Mesothelioma, bemcentinib/pembrolizumab is being compared to other targeted therapies (phase I/II, NCT03654833).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9092944\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9092944/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0375841347748804, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"17|28\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"3|15\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:d139e36eb2c481c4a9aa177917d2b81654ce9e6bb35b2e6d47440b2532c1f939\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/d139e36eb2c481c4a9aa177917d2b81654ce9e6bb35b2e6d47440b2532c1f939\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib entered clinical trials as the first Axl-specific inhibitor and is undergoing Phase I/II clinical trials for melanoma, non-small-cell lung cancer (NSCLC), mesothelioma, acute myeloid leukemia, glioblastoma, and pancreatic adenocarcinoma (Clinical Trial Identification Numbers: NCT02872259; NCT02922777; NCT03184571; NCT03654833; NCT03824080; NCT03965494; NCT03649321).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8469858\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8469858/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0375623329109331, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"167|179\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:26fc304e3c7f1b6469b4ae17c5d0fbdd35fad6ecfc37f51471a39770fa2406a3\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/26fc304e3c7f1b6469b4ae17c5d0fbdd35fad6ecfc37f51471a39770fa2406a3\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Bemcentinib is currently in phase II development for a variety of malignancies including NSCLC (NCT03184571), mesothelioma (NCT03654833), triple-negative breast cancer (NCT03184558), and melanoma (NCT02872259) in combination with pembrolizumab.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8992561\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8992561/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0373968463817334, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"0|11\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"110|122\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","3"],["object","MONDO:0005065"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9092944|PMC:8469858|PMC:8992561"],["score","1.0375144380225156"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:bd4521ba459bd717eb439c56b59979b8fb44ace89f6ea004205f33c40c88d34f|tmkp:d139e36eb2c481c4a9aa177917d2b81654ce9e6bb35b2e6d47440b2532c1f939|tmkp:26fc304e3c7f1b6469b4ae17c5d0fbdd35fad6ecfc37f51471a39770fa2406a3"]],["DRUGBANK:DB12411","biolink:treats_or_applied_or_studied_to_treat","MONDO:0005191",["upstream_resource_ids",["infores:text-mining-provider-targeted"]],["assertion_id","02c3072861cc201d5ffb9e81c3122b5e8744e91e62c4ad13f56966b7c1056659"],["association_curie","biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation"],["json_attributes","[{\"attribute_type_id\": \"biolink:knowledge_level\", \"value\": \"not_provided\"}, {\"attribute_type_id\": \"biolink:agent_type\", \"value\": \"text_mining_agent\"}, {\"attribute_type_id\": \"biolink:primary_knowledge_source\", \"value\": \"infores:text-mining-provider-targeted\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:supporting_data_source\", \"value\": \"infores:pubmed\", \"value_type_id\": \"biolink:InformationResource\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:evidence_count\", \"value\": 8, \"value_type_id\": \"biolink:EvidenceCount\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0735844476974952, \"value_type_id\": \"biolink:ConfidenceLevel\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": [\"PMC:9092944\", \"PMC:8750474\", \"PMC:8773625\", \"PMC:7072236\", \"PMC:8750474\"], \"value_type_id\": \"biolink:Uriorcurie\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:6a9aeedb6ed50cedc44bfa3867c79cf5fca1531b63491fd708bc7c69d25dc0fd\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/6a9aeedb6ed50cedc44bfa3867c79cf5fca1531b63491fd708bc7c69d25dc0fd\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"In metastatic melanoma, another study will assess bemcentinib in combination with pembrolizumab or dabrafenib/trametinib (phase I/II NCT02872259).\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:9092944\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC9092944/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"paragraph\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.073596178028828, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"50|61\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"3|22\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:bc1903c44d0090d490930423415d80107817b698fe26ade1209ad609bc9ec6d2\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/bc1903c44d0090d490930423415d80107817b698fe26ade1209ad609bc9ec6d2\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"Finally, a randomized phase Ib/II study of the selective small molecule AXL-inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma is ongoing, exploring the efficacy and role of sAXL to monitor minimal residual disease.\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8750474\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8750474/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"INTRO\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0735926868587884, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"86|97\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"196|215\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:95b4a4650d896e3d765e7a41277a79e95223577bb97750d825e4f447710a7fef\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/95b4a4650d896e3d765e7a41277a79e95223577bb97750d825e4f447710a7fef\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"A Randomized Phase Ib/II Study of the Selective Small Molecule Axl Inhibitor Bemcentinib (BGB324) in Combination with Either Dabrafenib/Trametinib (D/T) or Pembrolizumab in Patients with Metastatic Melanoma\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8773625\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8773625/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"reference\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.073583448685761, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"77|88\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"187|206\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2022, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:60a182fe058bd7e5105b7e7ea7b5e76c7ae8b1b613d2c3bdcf8a09076234e739\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/60a182fe058bd7e5105b7e7ea7b5e76c7ae8b1b613d2c3bdcf8a09076234e739\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:7072236\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC7072236/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"reference\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0735749624570494, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"77|88\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"181|200\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2020, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}, {\"attribute_type_id\": \"biolink:has_supporting_study_result\", \"value\": \"tmkp:b12e965ecb032156f9af5452bb750a07659b48f3d8405a5becc81e8c2b561a10\", \"value_type_id\": \"biolink:TextMiningResult\", \"value_url\": \"https://tmui.text-mining-kp.org/evidence/b12e965ecb032156f9af5452bb750a07659b48f3d8405a5becc81e8c2b561a10\", \"attribute_source\": \"infores:text-mining-provider-targeted\", \"attributes\": [{\"attribute_type_id\": \"biolink:supporting_text\", \"value\": \"A randomized phase Ib/II study of the selective small molecule axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma\", \"value_type_id\": \"EDAM:data_3671\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:publications\", \"value\": \"PMC:8750474\", \"value_type_id\": \"biolink:Uriorcurie\", \"value_url\": \"https://pubmed.ncbi.nlm.nih.gov/PMC8750474/\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:supporting_text_located_in\", \"value\": \"reference\", \"value_type_id\": \"IAO_0000314\", \"attribute_source\": \"infores:pubmed\"}, {\"attribute_type_id\": \"biolink:extraction_confidence_score\", \"value\": 1.0735749624570494, \"value_type_id\": \"EDAM:data_1772\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:subject_location_in_text\", \"value\": \"77|88\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted\"}, {\"attribute_type_id\": \"biolink:object_location_in_text\", \"value\": \"181|200\", \"value_type_id\": \"SIO:001056\", \"attribute_source\": \"infores:text-mining-provider-targeted \"}, {\"attribute_type_id\": \"biolink:supporting_document_year\", \"value\": 2021, \"value_type_id\": \"UO:0000036\", \"attribute_source\": \"infores:pubmed\"}]}]"],["mediKanren-score","5"],["object","MONDO:0005191"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["primary_knowledge_source","infores:text-mining-provider-targeted"],["publications","PMC:9092944|PMC:8750474|PMC:8773625|PMC:7072236|PMC:8750474"],["score","1.0735844476974952"],["subject","DRUGBANK:DB12411"],["supporting_study_results","tmkp:6a9aeedb6ed50cedc44bfa3867c79cf5fca1531b63491fd708bc7c69d25dc0fd|tmkp:bc1903c44d0090d490930423415d80107817b698fe26ade1209ad609bc9ec6d2|tmkp:95b4a4650d896e3d765e7a41277a79e95223577bb97750d825e4f447710a7fef|tmkp:60a182fe058bd7e5105b7e7ea7b5e76c7ae8b1b613d2c3bdcf8a09076234e739|tmkp:b12e965ecb032156f9af5452bb750a07659b48f3d8405a5becc81e8c2b561a10"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C4021734",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#t"],["id","UMLS:C4763383---SEMMEDDB:treats---None---None---None---UMLS:C4021734---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C4021734"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","treats"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:34219376)"],["publications_info","{\"PMID:34219376\":{\"object score\":\"1000\",\"publication date\":\"2021 Jul 05\",\"sentence\":\"Axl-inhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model.\",\"subject score\":\"790\"}}"],["relation_label","treats"],["source_predicate","SEMMEDDB:treats"],["subject","UMLS:C4763383"],["update_date","2021-07-07 13:01:50"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C3463824",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#f"],["id","UMLS:C4763383---SEMMEDDB:treats---None---None---None---UMLS:C3463824---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C3463824"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","treats"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:32136869)"],["publications_info","{\"PMID:32136869\":{\"object score\":\"1000\",\"publication date\":\"2018 Oct\",\"sentence\":\"The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS.\",\"subject score\":\"739\"}}"],["relation_label","treats"],["source_predicate","SEMMEDDB:treats"],["subject","UMLS:C4763383"],["update_date","2020-09-13 22:50:40"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C0041956",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#f"],["id","UMLS:C4763383---SEMMEDDB:treats---None---None---None---UMLS:C0041956---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C0041956"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","treats"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:34219376)"],["publications_info","{\"PMID:34219376\":{\"object score\":\"901\",\"publication date\":\"2021 Jul 05\",\"sentence\":\"Serum metabolomics analysis also showed a normalizing amino acid profile in UUO, compared with SHAM-operated mice following bemcentinib treatment.\",\"subject score\":\"888\"}}"],["relation_label","treats"],["source_predicate","SEMMEDDB:treats"],["subject","UMLS:C4763383"],["update_date","2021-07-07 13:01:51"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C0029162",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#t"],["id","UMLS:C4763383---SEMMEDDB:treats---None---None---None---UMLS:C0029162---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C0029162"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","treats"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:32440898)"],["publications_info","{\"PMID:32440898\":{\"object score\":\"901\",\"publication date\":\"2020 May 21\",\"sentence\":\"Based on the current observations, it can be assumed that oro-dental health might be significant also prior and during treatment with Bemcentinib for the prevention of MRONJ.\",\"subject score\":\"1000\"}}"],["relation_label","treats"],["source_predicate","SEMMEDDB:treats"],["subject","UMLS:C4763383"],["update_date","2020-09-15 22:17:30"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C0023467",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#f"],["id","UMLS:C4763383---SEMMEDDB:treats---None---None---None---UMLS:C0023467---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C0023467"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","treats"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:32440898)"],["publications_info","{\"PMID:32440898\":{\"object score\":\"1000\",\"publication date\":\"2020 May 21\",\"sentence\":\"Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML).\",\"subject score\":\"1000\"}}"],["relation_label","treats"],["source_predicate","SEMMEDDB:treats"],["subject","UMLS:C4763383"],["update_date","2020-09-15 22:17:30"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C0016059",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#f"],["id","UMLS:C4763383---SEMMEDDB:treats---None---None---None---UMLS:C0016059---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C0016059"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","treats"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:34861551)"],["publications_info","{\"PMID:34861551\":{\"object score\":\"1000\",\"publication date\":\"2021 Nov 30\",\"sentence\":\"Currently, the therapeutical approaches involving selected medications (bemcentinib, pirfenidone and nintedanib) obtained synthetically, and used in clinical practices for fibrosis and cancer management and treatment has shown to be unsatisfactorily, especially during progressive stages of the disease.\",\"subject score\":\"1000\"}}"],["relation_label","treats"],["source_predicate","SEMMEDDB:treats"],["subject","UMLS:C4763383"],["update_date","2021-12-06 15:23:47"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C0006826",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#f"],["id","UMLS:C4763383---SEMMEDDB:treats---None---None---None---UMLS:C0006826---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C0006826"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","treats"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:34861551)"],["publications_info","{\"PMID:34861551\":{\"object score\":\"888\",\"publication date\":\"2021 Nov 30\",\"sentence\":\"Currently, the therapeutical approaches involving selected medications (bemcentinib, pirfenidone and nintedanib) obtained synthetically, and used in clinical practices for fibrosis and cancer management and treatment has shown to be unsatisfactorily, especially during progressive stages of the disease.\",\"subject score\":\"1000\"}}"],["relation_label","treats"],["source_predicate","SEMMEDDB:treats"],["subject","UMLS:C4763383"],["update_date","2021-12-06 15:23:47"]],["UMLS:C4763383","biolink:treats_or_applied_or_studied_to_treat","UMLS:C0027361",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#t"],["id","UMLS:C4763383---SEMMEDDB:administered_to---None---None---None---UMLS:C0027361---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C0027361"],["predicate","biolink:treats_or_applied_or_studied_to_treat"],["predicate_label","administered_to"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:35492873)"],["publications_info","{\"PMID:35492873\":{\"object score\":\"877\",\"publication date\":\"2022 Mar 15\",\"sentence\":\"NSCLC-affected individuals with identified    STK11/LKB1     mutations receiving bemcentinib and pembrolizumab demonstrated objective clinical response to combination therapy.\",\"subject score\":\"1000\"}}"],["relation_label","administered_to"],["source_predicate","SEMMEDDB:administered_to"],["subject","UMLS:C4763383"],["update_date","2022-05-10 18:25:26"]],["UMLS:C4763383","biolink:preventative_for_condition","UMLS:C0042769",["upstream_resource_ids",["infores:rtx-kg2"]],["agent_type","text_mining_agent"],["domain_range_exclusion","#f"],["id","UMLS:C4763383---SEMMEDDB:prevents---None---None---None---UMLS:C0042769---SEMMEDDB:"],["knowledge_level","prediction"],["mediKanren-score","1"],["negated","#f"],["object","UMLS:C0042769"],["predicate","biolink:preventative_for_condition"],["predicate_label","prevents"],["primary_knowledge_source","infores:semmeddb"],["publications","(PMID:32736596)"],["publications_info","{\"PMID:32736596\":{\"object score\":\"1000\",\"publication date\":\"2020 Jul 31\",\"sentence\":\"Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein.\",\"subject score\":\"1000\"}}"],["relation_label","prevents"],["source_predicate","SEMMEDDB:prevents"],["subject","UMLS:C4763383"],["update_date","2020-09-07 19:02:14"]]]